Blue Cone Monochromacy

Mendelian MONDO:0010563 Pathograph 15 Show in embeddings browser Cone dysfunction syndrome Inherited retinal disease

Blue cone monochromacy is an X-linked recessive cone dysfunction syndrome in which the long-wavelength (L, "red") and middle-wavelength (M, "green") cone photoreceptors are non-functional while short-wavelength (S, "blue") cones and rods are preserved. The lesion is at the OPN1LW/OPN1MW opsin gene array on Xq28, and its architecture is what makes the disease unusual: the two opsin genes sit head-to-tail with more than 98% sequence identity, and a single upstream locus control region (LCR) loops to one promoter at a time to enforce mutually exclusive expression of one opsin per cone. Because one LCR governs both genes, a single regulatory deletion silences the whole array — so a disorder that would otherwise require two independent hits is reachable in one step. The two commonest routes are exactly these: deletion of the LCR, and unequal crossing-over that collapses the array to a single gene which then carries the recurrent inactivating Cys203Arg substitution. Clinically this produces reduced but not absent visual acuity (roughly 20/60 to 20/200), pendular nystagmus, photophobia, myopia, and colour discrimination that fails on the protan and deutan axes while retaining tritan discrimination — the preserved blue-yellow axis being the finding that separates it from complete achromatopsia at the bedside. The disorder was long taught as stationary, and the honest position is that this is only partly true: several families show psychophysical and structural progression, and progression rate tracks genotype, with large deletions degenerating faster than Cys203Arg. That genotype-dependence is not a curiosity but the central problem for the gene-therapy programmes now developing outcome measures for this disease, since it determines how wide the treatment window is and for whom.

Ask OpenScientist

Ask a research question about Blue Cone Monochromacy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
8
Phenotypes
2
Gaps
15
Pathograph
6
Genes
2
Medical Actions
2
Differentials
2
Models
15
References
1
Deep Research
👪

Inheritance

1
X-linked recessive HP:0001419
Affected individuals are essentially all hemizygous males. Carrier females are usually clinically unaffected but are not biologically silent — see the carrier node in pathophysiology — and completely skewed X-inactivation can produce a manifesting female.
X-linked recessive inheritance
Show evidence (1 reference)
PMID:22998501 SUPPORT Human Clinical
"Blue cone monochromatism (BCM) is a rare cone dystrophy with recessive X-linked inheritance and therefore diagnosed in males whereas females are clinically unaffected."
States the inheritance mode and the sex distribution it produces.
?

Discussions and Knowledge Gaps

2
Is blue cone monochromacy a stationary cone dysfunction syndrome or a slowly progressive dystrophy, and how much of the disagreement is explained by genotype rather than by measurement sensitivity?
CONTROVERSY bcm_stationary_versus_progressive
Attached to
pathophysiology#Cone Outer Segment Disruption and Progressive Foveal Cone Loss phenotypes#Progressive Loss of Cone Function
The disorder is classified among the stationary cone dysfunction syndromes, and many families do appear stable. But progression has been demonstrated psychophysically in individual families, macular atrophy develops in a subset, OCT shows an age-related effect on foveal disease stage, and the rate differs between large-deletion and Cys203Arg genotypes. Curating this as simply "stationary" would be wrong, and curating it as simply "progressive" would overstate what is shown for most patients. The unresolved part is whether the apparently stable majority are genuinely stable or merely followed for too short a time with insufficiently sensitive measures — which matters directly, because a bounded therapeutic window is the main design constraint on the gene therapy programmes.
Proposed experiments
Longitudinal genotype-stratified AOSLO and microperimetry cohort
bcm_longitudinal_genotype_stratified_aoslo
Follow LCR-deletion and Cys203Arg cohorts prospectively with adaptive-optics cone density, OCT outer nuclear layer thickness, and dark-adapted red microperimetry, to establish whether the stable-appearing majority show measurable decline on sensitive endpoints and to quantify the window per genotype.
Show evidence (3 references)
PMID:15094734 SUPPORT Human Clinical
"In two families, psychophysical testing demonstrated evidence for progression of disease."
Evidence for the progressive side of the question.
PMID:10982039 SUPPORT Human Clinical
"Progressive macular atrophy was observed in affected members of two BCM families while the rest of the families presented with normal fundus."
Shows that progression is a subset finding, which is the other side of the controversy.
PMID:41941983 SUPPORT Model Organism
"Despite the loss of cone outer segments, cone photoreceptor cells remained viable, even up to 6 months of age in hemizygous and homozygous mutant mice."
Model-organism evidence bearing on the stationary side: in the allele equivalent to Cys203Arg, the cone loses its outer segment without dying, which is a mechanism for structural change without progressive cell loss. PARTIAL because six mouse months cannot speak to decades of human disease.
Does genotype at the opsin array predict the clinical phenotype, given that one series found no genotype-phenotype association while later structural work found deletion genotypes progress faster than Cys203Arg?
OPEN QUESTION bcm_genotype_phenotype_correlation
Attached to
pathophysiology#Loss of Function of the OPN1LW/OPN1MW Opsin Gene Array
These findings are not straightforwardly contradictory — the earlier study assessed cross-sectional clinical and electrophysiological phenotype, the later work assessed rate of structural change — but they are routinely quoted against each other. Resolving which phenotypic dimensions genotype predicts (baseline severity versus rate of decline) is what a counselling statement or a trial stratification would actually need.
Show evidence (3 references)
PMID:10982039 SUPPORT Human Clinical
"No association was observed between the phenotypes and genotypes in these families."
The negative cross-sectional finding.
PMID:39408969 SUPPORT Human Clinical
"However, foveal structural changes tend to progress faster in patients with large deletions as compared with the point mutation"
The positive longitudinal-structural finding on the other side.
PMID:35400991 SUPPORT Human Clinical
"Blue cone monochromacy (BCM) is an X-linked retinopathy caused by mutations in the red and green cone opsin genes. The aim of this study was to establish the clinical, genetic, and electrophysiological characteristics of a specific form of BCM."
Cited as a study framed around a haplotype-defined milder form, which is evidence that genotype tracks severity in at least some direction; PARTIAL because only the framing, not a quantified correlation, is quotable from the cached abstract.
⚙

Pathophysiology

6
Loss of Function of the OPN1LW/OPN1MW Opsin Gene Array
The initiating lesion. Both the L and M opsin genes on Xq28 must lose function; loss of only one produces ordinary red-green colour blindness, not this disorder. Two mutational routes dominate. The first is deletion of the locus control region 3.1-3.7 kb upstream of the array, which silences every gene downstream of it. The second is unequal homologous recombination that collapses the array to a single gene or a 5'L-M-3' hybrid, which then carries an inactivating point substitution — most often Cys203Arg, and less often Arg247Ter or Pro307Leu. High-resolution X-chromosome microarray has since resolved more complex rearrangements, including a founder allele combining a 3-kb LCR deletion with insertion of an aberrant OPN1MW gene.
OPN1LW hgnc:9936 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves OPN1LW (hgnc:9936). hgnc:9936 is a gene from the HUGO Gene Nomenclature Committee. OPN1MW hgnc:4206 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves OPN1MW (hgnc:4206). hgnc:4206 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context functional_impact_category: LOSS_OF_FUNCTION
Downstream
Failure of Locus Control Region-Driven Opsin Expression Deletion of the locus control region removes the enhancer that both opsin promoters depend on.
Absent or Non-Functional L and M Cone Photopigment Inactivating coding substitutions in a collapsed single-gene array leave the cone without usable photopigment even when transcription proceeds.
Show evidence (4 references)
PMID:8213841 SUPPORT Human Clinical
"As observed in an earlier study, the rearrangements involve either deletion of a locus control region adjacent to the gene array or loss of function via homologous recombination and point mutation."
Establishes the two dominant mutational routes that this node represents.
PMID:8213841 SUPPORT Human Clinical
"Two other point mutations were identified: (a) Arg247-to-Ter in one subject with a single red-pigment gene and (b) Pro307-to-Leu in one subject with a single 5' red-3' green hybrid gene."
Documents the additional inactivating substitutions named in this node.
PMID:26153062 SUPPORT Human Clinical
"In two families, we identified a novel founder mutation that consisted of a complex 3-kb deletion that embraced the cis-regulatory locus control region and insertion of an additional aberrant OPN1MW gene."
Documents the complex rearrangement class that PCR-based testing missed.
+ 1 more reference
Failure of Locus Control Region-Driven Opsin Expression
The regulatory arm, and the reason a single deletion suffices. A locus control region between 3.1 and 3.7 kb upstream of the L opsin transcription start site is essential for expression of the adjacent visual pigment genes, and the mutually exclusive choice of one opsin per cone is set by competition between the two pigment promoters for pairing with that single LCR. Deleting it therefore does not silence one gene, it silences the array — converting what would need to be two independent inactivating events into one.
retinal cone cell CL:0000573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal cone cell (CL:0000573). CL:0000573 is a cell type from the Cell Ontology.
OPN1LW hgnc:9936 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves OPN1LW (hgnc:9936). hgnc:9936 is a gene from the HUGO Gene Nomenclature Committee.
regulation of DNA-templated transcription GO:0006355 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent regulation of DNA-templated transcription (GO:0006355). GO:0006355 is a biological process from the Gene Ontology. ∅ ABSENT
Downstream
Absent or Non-Functional L and M Cone Photopigment With the enhancer gone, neither opsin promoter is transcribed in cones that would otherwise express L or M opsin.
Show evidence (4 references)
PMID:1524826 SUPPORT Model Organism
"a region between 3.1 kb and 3.7 kb 5' of the red pigment gene transcription initiation site is essential for expression"
Transgenic-mouse mapping of the enhancer whose deletion causes the disease.
PMID:1524826 SUPPORT Human Clinical
"Deletion of sequences 5' of the human red and green pigment gene array results in blue cone monochromacy, a disorder in which both red and green cone function are absent."
States the human genotype-phenotype relationship this node encodes.
PMID:11773636 SUPPORT Model Organism
"The results support a model in which the mutually exclusive expression of these genes in their respective cone types is controlled by competition between visual pigment promoters for pairing with the LCR"
Gives the regulatory model — one LCR shared by both promoters — that makes a single deletion sufficient.
+ 1 more reference
Absent or Non-Functional L and M Cone Photopigment
The convergence point of both mutational routes. Cones that should express L or M opsin either make no opsin at all (deletion genotypes) or make an unstable, non-functional one (Cys203Arg disrupts a conserved disulfide bond required for correct folding of the seven-transmembrane opsin GPCR). Opsin is not only the light sensor but a structural requirement for building and maintaining the cone outer segment, so an opsin-null cone is compromised as a cell, not merely blind.
L cone cell CL:0003048 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves L cone cell (CL:0003048). CL:0003048 is a cell type from the Cell Ontology. M cone cell CL:0003049 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves M cone cell (CL:0003049). CL:0003049 is a cell type from the Cell Ontology.
phototransduction GO:0007602 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent phototransduction (GO:0007602). GO:0007602 is a biological process from the Gene Ontology. ∅ ABSENT
G protein-coupled photoreceptor activity GO:0008020 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves absent G protein-coupled photoreceptor activity (GO:0008020). GO:0008020 is a molecular function from the Gene Ontology. ∅ ABSENT
Animal models
Opn1mw C198R knock-in mouse Mouse recapitulates Diminished M-opsin expression with mislocalization, and loss of cone outer segments in M-cone photoreceptors — the structural consequence this node asserts.
Opn1mw knockout mouse Mouse recapitulates Cones lacking M-opsin, the null counterpart of the human deletion class.
Opn1mw knockout mouse Mouse rescues AAV5-delivered recombinant M-opsin restored M-cone function, establishing that an opsin-null cone remains competent to be rescued — the premise the entire gene-therapy strategy rests on.
Downstream
Cone Outer Segment Disruption and Progressive Foveal Cone Loss Absence of opsin destabilizes the outer segment and, over time, the cone itself.
Vision Mediated by Preserved S Cones and Rods With L and M cones silent, daylight vision falls back onto the S cones and partially desensitized rods.
Show evidence (2 references)
PMID:8213841 SUPPORT Human Clinical
"One inactivating mutation, Cys203-to-Arg, was found in 15 probands who carry single genes and in both visual pigment genes in one subject whose array has two genes."
Establishes Cys203Arg as the dominant inactivating substitution.
PMID:37001420 SUPPORT Human Clinical
"Similar to rhodopsin in rods, cone opsins are crucial in both the maintenance and structural integrity of the cone outer segment, the light-sensing organelle of the cell."
States the structural, not merely sensory, role of opsin that makes an opsin-null cone structurally vulnerable.
Cone Outer Segment Disruption and Progressive Foveal Cone Loss
Foveal cones are structurally abnormal from early in life and decline further with age. Adaptive-optics imaging shows reduced total cone density with the majority of the remaining population non-waveguiding — that is, present as cells but not functioning as light guides. This is why the "stationary disorder" framing is only partly right: outer retinal changes are detectable on OCT with an age-related effect on foveal disease stage, and psychophysical progression has been demonstrated in individual families. Progression is genotype-dependent, with large deletions advancing faster than the Cys203Arg substitution.
retinal cone cell CL:0000573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal cone cell (CL:0000573). CL:0000573 is a cell type from the Cell Ontology.
photoreceptor cell outer segment organization GO:0035845 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal photoreceptor cell outer segment organization (GO:0035845). GO:0035845 is a biological process from the Gene Ontology. ⚠ ABNORMAL
fovea centralis UBERON:0001786 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in fovea centralis (UBERON:0001786). UBERON:0001786 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Opn1mw C198R knock-in mouse Mouse partially recapitulates Reproduces outer-segment loss but not cone death: mutant cones remained viable to six months in both hemizygous and homozygous animals, and the authors contrast this explicitly with the toxic-aggregate mechanism of rhodopsin mutants in retinitis pigmentosa.
Show evidence (5 references)
PMID:39408969 SUPPORT Human Clinical
"AOSLO imaging showed reduced total cone density with majority of the population being non-waveguiding."
Direct structural measurement of the residual foveal cone population.
PMID:39408969 SUPPORT Human Clinical
"Outer retinal changes were detectable by OCT with an age-related effect on the foveal disease stage."
Supports an age-related structural component rather than a purely stationary disorder.
PMID:39408969 SUPPORT Human Clinical
"However, foveal structural changes tend to progress faster in patients with large deletions as compared with the point mutation"
States the genotype-dependence of progression rate.
+ 2 more references
Vision Mediated by Preserved S Cones and Rods
What is left, and why the phenotype is what it is. S cones (OPN1SW, on chromosome 7) and rods are genetically untouched, so daylight vision is carried by the S-cone population — only a few percent of all cones, sparse in the fovea — together with rods operating partially desensitized in photopic conditions. That residual system explains the clinical picture directly: acuity is reduced but far from absent, colour discrimination survives on the tritan axis while failing on protan and deutan axes, and night vision is typically healthy. It is also the finding that separates this disorder from complete achromatopsia, where all cone signal is extinguished.
S cone cell CL:0003050 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves S cone cell (CL:0003050). CL:0003050 is a cell type from the Cell Ontology. retinal rod cell CL:0000604 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal rod cell (CL:0000604). CL:0000604 is a cell type from the Cell Ontology.
visual perception GO:0007601 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal visual perception (GO:0007601). GO:0007601 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (5 references)
PMID:39408969 SUPPORT Human Clinical
"Most BCM patients have healthy night vision mediated by functioning rod photoreceptors."
Establishes preserved rod-mediated scotopic vision.
PMID:39408969 SUPPORT Human Clinical
"Importantly, the daylight vision of BCM patients is mediated by the combination of short-wavelength-sensitive (S) cone photoreceptors and rod photoreceptors that function in a partially desensitized manner in a daylight environment"
States precisely which photoreceptor populations carry residual photopic vision.
PMID:15094734 SUPPORT Human Clinical
"Affected males were shown to fail the protan and deutan axes, but retained good discrimination on the tritan axis of the MR test, a compelling evidence for residual colour vision in BCM."
The psychophysical signature of preserved S-cone function.
+ 2 more references
Carrier Female Cone Mosaic Disruption
Carrier females are described as unaffected, but they are not unaffected at the level of the retina. Random X-inactivation means roughly half of the cones fated to express L or M opsin instead express nothing, and imaging those retinas shows reduced cone density and disrupted mosaic organization relative to normal trichromats — evidence that opsin-null cones degenerate early rather than persisting silently. This is the cleanest natural experiment supporting the structural role of opsin asserted in the parent node, and it is the mechanism behind the rare manifesting female, in whom X-inactivation is completely skewed rather than random.
retinal cone cell CL:0000573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal cone cell (CL:0000573). CL:0000573 is a cell type from the Cell Ontology.
Show evidence (3 references)
PMID:20638402 SUPPORT Human Clinical
"On average, they had cone mosaics with reduced density and disrupted organization compared to normal trichromats."
The imaging result in LCR-deletion carrier females.
PMID:20638402 SUPPORT Human Clinical
"This suggests that the absence of opsin in a subset of cones results in their early degeneration, with X-inactivation the likely mechanism underlying phenotypic variability in BCM carriers."
States both the degeneration inference and the X-inactivation mechanism.
PMID:22998501 SUPPORT Human Clinical
"The diagnosis was genetically verified with the identification of one single red-green OPN1LW/MW hybrid gene harboring a point mutation c.607C>G, p.Cys203Arg that associates with BCM and in addition a completely biased X-inactivation in DNA isolated from full blood and buccal mucosa."
Documents the completely skewed X-inactivation behind a manifesting female.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Blue Cone Monochromacy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Eye 7
Severe Color Vision Defect with Preserved Tritan Discrimination OBLIGATE HP:0000551 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Color vision defect (HP:0000551). HP:0000551 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:15094734 SUPPORT Human Clinical
"Affected males were shown to fail the protan and deutan axes, but retained good discrimination on the tritan axis of the MR test, a compelling evidence for residual colour vision in BCM."
Directly reports the axis-selective pattern.
PMID:39408969 SUPPORT Human Clinical
"Color vision was severely deficient. AOSLO imaging showed reduced total cone density with majority of the population being non-waveguiding."
Confirms the severity of the colour deficit in a genotyped cohort.
Reduced Visual Acuity OBLIGATE HP:0007663 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced visual acuity (HP:0007663). HP:0007663 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10982039 SUPPORT Human Clinical
"Acuities were reduced in all affected males, and photopic b-wave was reduced by more than 90% in seven families."
Establishes reduced acuity as universal across ten families.
Nystagmus VERY_FREQUENT HP:0000639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nystagmus (HP:0000639), qualified as infantile onset. HP:0000639 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (1 reference)
PMID:10982039 SUPPORT Human Clinical
"Blue cone monochromacy (BCM) is an X-linked ocular disease characterized by poor visual acuity, nystagmus, and photodysphoria in males with severely reduced color discrimination."
Lists nystagmus among the defining clinical features.
Photophobia VERY_FREQUENT HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10982039 SUPPORT Human Clinical
"Blue cone monochromacy (BCM) is an X-linked ocular disease characterized by poor visual acuity, nystagmus, and photodysphoria in males with severely reduced color discrimination."
Photodysphoria is the historical term for the light sensitivity recorded here.
Myopia FREQUENT HP:0000545 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myopia (HP:0000545). HP:0000545 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37001420 SUPPORT Human Clinical
"BCM patients typically suffer from poor visual acuity, severely impaired color discrimination, myopia, and nystagmus."
Lists myopia among the typical features.
Severely Reduced Photopic Cone Electroretinogram VERY_FREQUENT Abnormal electroretinogram HP:0000512 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal electroretinogram (HP:0000512). HP:0000512 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10982039 SUPPORT Human Clinical
"Acuities were reduced in all affected males, and photopic b-wave was reduced by more than 90% in seven families."
Quantifies the photopic ERG reduction.
PMID:10982039 SUPPORT Human Clinical
"In three families, however, the photopic b-wave response showed uncharacteristic relative preservation of 30-80% (of the clinical low-normal value)."
The exception that keeps this phenotype from being curated as invariably absent.
Progressive Loss of Cone Function OCCASIONAL Reduced visual acuity HP:0007663 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced visual acuity (HP:0007663), qualified as course progressive. HP:0007663 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:15094734 SUPPORT Human Clinical
"In two families, psychophysical testing demonstrated evidence for progression of disease."
Demonstrates progression psychophysically in a subset of families.
PMID:19421413 SUPPORT Human Clinical
"A novel mutation was detected in Family 2 that had a single hybrid gene lacking exon 2. This family presented clinical and psychophysical evidence of a slowly progressive phenotype."
Ties a progressive phenotype to a specific genotype, supporting genotype dependence.
Other 1
Progressive Macular Atrophy OCCASIONAL Macular degeneration HP:0000608 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macular degeneration (HP:0000608), qualified as course progressive. HP:0000608 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:10982039 SUPPORT Human Clinical
"Progressive macular atrophy was observed in affected members of two BCM families while the rest of the families presented with normal fundus."
Gives both the finding and the denominator that justifies the OCCASIONAL band.
🧬

Genetic Associations

6
OPN1LW/OPN1MW opsin gene array (Genetic Mutation)
Gene: OPN1LW hgnc:9936 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPN1LW (hgnc:9936). hgnc:9936 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
X-linked recessive
Show evidence (2 references)
PMID:26153062 SUPPORT Human Clinical
"Blue cone monochromacy (BCM) is an X-linked condition caused by a loss-of-function of both the OPN1LW and OPN1MW opsin genes."
States the two-gene loss-of-function requirement.
PMID:26153062 SUPPORT Human Clinical
"The cone opsin gene cluster is composed of 2-9 paralogs with 99.8% sequence homology and is susceptible to deletions, duplications, and mutations."
Explains the locus architecture that makes recurrent rearrangement the dominant mutational mechanism.
OPN1MW (Genetic Mutation)
Gene: OPN1MW hgnc:4206 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPN1MW (hgnc:4206). hgnc:4206 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
X-linked recessive
Show evidence (1 reference)
PMID:10982039 SUPPORT Human Clinical
"In one family no mutation was found in the exons of the red gene or the locus control region but showed loss of the complete green gene."
Documents the genotype in which the M gene is the demonstrable lesion.
Locus control region deletion (Genetic Mutation)
Gene: OPN1LW hgnc:9936 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPN1LW (hgnc:9936). hgnc:9936 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
X-linked recessive
Show evidence (1 reference)
PMID:35759666 SUPPORT Human Clinical
"However, 90% of SVs encompass the upstream locus control region, an essential enhancer element. Its minimal functional extent based on deletion mapping in patients was refined to 358 bp."
Quantifies how often the enhancer is involved and gives the patient-derived minimal functional extent.
Structural variant landscape of the OPN1LW/OPN1MW cluster (Genetic Mutation)
Gene: OPN1MW hgnc:4206 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPN1MW (hgnc:4206). hgnc:4206 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:35759666 SUPPORT Human Clinical
"We found that about one-third (n = 73) of the 213 molecularly confirmed BCM families carry an SV, most commonly deletions restricted to the OPN1LW/OPN1MW gene cluster."
Quantifies the share of families with a structural variant.
PMID:35759666 SUPPORT Human Clinical
"In total, 42 distinct SVs were identified, including 40 previously unreported SVs, thereby quadrupling the number of precisely mapped SVs underlying BCM. Notably, there was no "region of overlap" among these SVs."
Establishes both the diversity of variants and the absence of a common minimal region.
PMID:35759666 SUPPORT Human Clinical
"Using parsimonious assumptions, we reconstructed the composition and copy number of the OPN1LW/OPN1MW gene cluster prior to the mutation event and found evidence that large gene arrays may be predisposed to the occurrence of SVs at this locus."
Links array size to structural-variant susceptibility, supporting the architectural argument.
GPR143 (Disease-associated)
Gene: GPR143 hgnc:20145 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GPR143 (hgnc:20145). hgnc:20145 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER
Show evidence (1 reference)
PMID:34445325 SUPPORT Human Clinical
"To our knowledge, this is the first case of foveal hypoplasia in a BCM patient and of mild clinical affection in a female carrier caused by the concomitant effect of variants in OPN1LW/OPN1MW and GPR143 genes, thus as the result of the simultaneous action of two independent genetic defects."
Single-case evidence for a second-locus modifier effect; PARTIAL because it rests on one family.
Cys203Arg recurrent inactivating substitution (Genetic Mutation)
Gene: OPN1LW hgnc:9936 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPN1LW (hgnc:9936). hgnc:9936 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:8213841 SUPPORT Human Clinical
"This mutation was also found in at least one of the visual pigment genes in 1 subject whose array has multiple genes and in 2 of 321 control subjects, suggesting that preexisting Cys203-to-Arg mutations constitute a reservoir of chromosomes that are predisposed to generate blue-cone-monochromat..."
States the reservoir hypothesis that explains recurrence of this allele.
💊

Medical Actions

2
Tinted Lenses and Low Vision Aids
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
The whole of current management. Tinted lenses reduce photophobia and improve contrast; low-vision aids address the acuity deficit. Nothing available today modifies the underlying disease.
Target Phenotypes: Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39408969 SUPPORT Human Clinical
"There are currently no treatments for BCM, and management of the disease is limited to the use of tinted lenses and low vision aids."
States both the absence of disease-modifying therapy and the content of current management.
AAV-Mediated L-Opsin Gene Augmentation (investigational)
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
The therapeutic strategy in development: deliver a functional L-opsin gene to residual L/M cones by adeno-associated virus. It is investigational, not approved, and is recorded here as a research programme rather than a treatment option. Its central design problem follows directly from the pathophysiology above — the residual cones are largely non-waveguiding and decline with age, so the therapeutic window is bounded and strongly age-dependent. Genotype governs the rate of progression rather than the width of the window: the two mouse models compared so far showed similar windows despite different genotypes. Much of the recent clinical literature is accordingly about building outcome measures sensitive enough to detect an L-cone-specific gain. Route of delivery is itself a design constraint here: subretinal injection risks the very foveal structure that is the therapeutic target, which is why an intravitreal vector was developed.
Mechanism Target:
RESTORES Absent or Non-Functional L and M Cone Photopigment — Gene augmentation aims to restore L-opsin expression in surviving cones; it cannot recover cones already lost, which is why the timing question is central.
Show evidence (1 reference)
PMID:39408969 SUPPORT Human Clinical
"L-cone opsin expression by gene therapy is a promising treatment for blue cone monochromacy (BCM) caused by congenital lack of long- and middle-wavelength-sensitive (L/M) cone function."
States the therapeutic rationale and its molecular target.
Show evidence (5 references)
PMID:36932675 SUPPORT Model Organism
"A single IVT administration dose of ADVM-062 effectively transduced gerbil cone photoreceptors and produced a de novo response to long-wavelength stimuli."
Preclinical proof that an intravitreally delivered L-opsin vector produces a new long-wavelength response, in an animal whose cone-rich retina naturally lacks L-opsin.
PMID:36932675 SUPPORT Model Organism
"However, most experimental ocular gene therapies utilize subretinal vector injection which would pose a risk to the fragile central retinal structure of BCM patients."
Supports the delivery-route constraint stated in the description.
PMID:39408969 SUPPORT Human Clinical
"This study developed and evaluated specialized outcomes that will be needed for the determination of efficacy and safety in human clinical trials."
Confirms that human trials are prospective rather than completed, which is why this is curated as investigational.
+ 2 more references
🔬

Diagnosis

3
Full-Field Electroretinography
The key functional test. Rod-specific and mixed rod-cone responses are normal or near-normal while the L/M-cone-driven photopic response is severely reduced or absent, and S-cone-isolating stimuli still elicit a response. It is that dissociation, not the absolute amplitudes, that makes the diagnosis.
Show evidence (2 references)
PMID:10982039 SUPPORT Human Clinical
"Acuities were reduced in all affected males, and photopic b-wave was reduced by more than 90% in seven families."
Quantifies the photopic reduction that anchors the ERG diagnosis.
PMID:38871951 SUPPORT Human Clinical
"The aim of this exploratory study is to investigate the role of S-cones in oscillatory potentials (OPs) generation by individuals with blue-cone monochromacy (BCM), retaining S-cones, and achromatopsia (ACHM), lacking cone functions."
Frames the retained-S-cone versus absent-cone-function contrast that the ERG exploits; PARTIAL because the study itself examines an ancillary oscillatory-potential signature rather than validating the diagnostic test.
Colour Vision Testing
Farnsworth D-15 gives protan-like arrangements. The Mollon-Reffin Minimal test is particularly useful because it resolves the retained tritan axis, and HRR plates detect the same residual discrimination.
Show evidence (4 references)
PMID:15094734 SUPPORT Human Clinical
"In addition, we have demonstrated that the Mollon-Reffin (MR) Minimal test is a useful colour-discrimination test to aid in the diagnosis of BCM."
Identifies the colour test with the best discriminating value here.
PMID:15094734 SUPPORT Human Clinical
"We have confirmed the reported finding of protan-like D-15 arrangements of patients with BCM."
Documents the D-15 pattern.
PMID:36692456 SUPPORT Human Clinical
"With D-15, there was protan-deutan confusion and no bimodal tendency."
Characterizes the D-15 result pattern specific to this disorder.
+ 1 more reference
Molecular Testing of the Xq28 Opsin Array
Standard short-read exome pipelines are unreliable at this locus because the paralogs are about 99.8% identical, so a negative exome does not exclude the diagnosis. Targeted approaches — long-range PCR, Southern blot, and high-resolution X-chromosome microarray — are required, and microarray in particular resolves alterations that PCR-based testing leaves undetermined in around 10% of patients and extends testing to female carriers.
Genetic Testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:26153062 SUPPORT Human Clinical
"Current diagnostic tests employ polymerase chain reaction (PCR)-based technologies; however, alterations remain undetermined in 10% of patients. Furthermore, carrier testing in females is limited or unavailable."
States the diagnostic gap that motivates microarray-based testing.
PMID:26153062 SUPPORT Human Clinical
"Pathogenic alterations were revealed in all probands, characterized by sequencing of the breakpoint junctions and quantitative real-time PCR."
Demonstrates the diagnostic yield of the microarray approach.
📊

Prevalence

1
Worldwide
Point Prevalence 1.0 per 100,000 1–9 per 100,000
Approximately 1 in 100,000 worldwide. Note that this is a rate over the whole population; because the disorder is X-linked recessive, the rate among males is correspondingly higher.
Show evidence (1 reference)
PMID:37001420 SUPPORT Human Clinical
"It is estimated that BCM affects approximately 1 in 100,000 people worldwide"
Source of the prevalence estimate.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Blue Cone Monochromacy:

Achromatopsia MONDO:0018852
Overlapping Features Autosomal recessive complete cone dysfunction (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, ATF6) affecting all three cone classes rather than only L and M. It is the principal differential, and the electroretinogram is what settles it.
Distinguishing Features
  • All cone signal extinguished on ERG, including S-cone-isolating stimuli
  • No retained tritan axis on colour testing
  • Typically worse visual acuity
  • Hyperopia more typical than myopia
  • Autosomal recessive rather than X-linked inheritance
Show evidence (2 references)
PMID:38871951 SUPPORT Human Clinical
"The aim of this exploratory study is to investigate the role of S-cones in oscillatory potentials (OPs) generation by individuals with blue-cone monochromacy (BCM), retaining S-cones, and achromatopsia (ACHM), lacking cone functions."
States the retained-S-cone versus absent-cone-function contrast that separates the two disorders.
PMID:36186895 SUPPORT Human Clinical
"Foveal hypoplasia was significantly more prevalent in ACHM than in BCM (p<0.001)."
Quantifies the foveal-hypoplasia difference that helps separate the two on OCT.
X-linked cone dystrophy
Overlapping Features Missense variants in the same L/M opsin genes can produce X-linked cone dystrophy or high myopia with abnormal cone function rather than this disorder, so the same locus spans a phenotypic range and genotype alone does not settle the diagnosis.
Distinguishing Features
  • Progressive cone degeneration rather than a predominantly congenital deficit
  • A different pattern of L/M opsin missense alleles at the same locus
Show evidence (1 reference)
PMID:37001420 SUPPORT Human Clinical
"X-linked retinal diseases resulting from mutations in the L- (OPN1LW, OMIM *300822) and M- (OPN1MW, OMIM *300821) opsin gene cluster are associated with a wide range of visual defects, including red/green color vision deficiency, X-linked cone dystrophy/dysfunction, high myopia with abnormal..."
Establishes that the same locus produces a spectrum of distinct diagnoses.
🐁

Animal Models

2
Opn1mw C198R knock-in mouse
The mouse counterpart of the commonest human missense allele. Because murine M-opsin is five residues shorter at the amino terminus, the equivalent substitution is numbered C198R.
Species
Mouse
Genotype
Opn1mw C198R knock-in (murine equivalent of human OPN1MW Cys203Arg)
Publication
PMID:41941983
Pathograph links
Absent or Non-Functional L and M Cone Photopigment recapitulates fidelity: high Diminished M-opsin expression with mislocalization, and loss of cone outer segments in M-cone photoreceptors — the structural consequence this node asserts.
Limitations: Mouse has no L-opsin at all, so the model reproduces only the M-cone half of the human two-opsin lesion; and in vitro the mutant aggregates while in vivo it does not, so cell-culture results from this allele overstate the in vivo severity.
Show evidence (1 reference)
PMID:41941983 SUPPORT Model Organism
"The mutation diminished the expression of M-opsin with some apparent mislocalization of the cone opsin without aggregation, which resulted in the loss of cone outer segments in M-cone photoreceptor cells."
The in vivo structural result linking the allele to outer-segment loss.
Cone Outer Segment Disruption and Progressive Foveal Cone Loss partially recapitulates fidelity: moderate Reproduces outer-segment loss but not cone death: mutant cones remained viable to six months in both hemizygous and homozygous animals, and the authors contrast this explicitly with the toxic-aggregate mechanism of rhodopsin mutants in retinitis pigmentosa.
Limitations: Six months of mouse life cannot address decades of human disease, so a viable cone at six months does not establish that the human Cys203Arg cone survives — it establishes that a toxic-aggregate death mechanism is not operating early. This is why the entry treats slow Cys203Arg progression as observed rather than mechanistically explained.
Show evidence (2 references)
PMID:41941983 SUPPORT Model Organism
"Despite the loss of cone outer segments, cone photoreceptor cells remained viable, even up to 6 months of age in hemizygous and homozygous mutant mice."
The dissociation between outer-segment loss and cone survival.
+ 1 more reference
Opn1mw knockout mouse
An opsin-null model built explicitly as the mouse stand-in for the human deletion genotype, and the vehicle for the first cone-rescue proof of concept.
Species
Mouse
Genotype
Opn1mw -/- (M-opsin knockout, expressing only S-opsin)
Publication
PMID:28751656
Pathograph links
Absent or Non-Functional L and M Cone Photopigment recapitulates fidelity: moderate Cones lacking M-opsin, the null counterpart of the human deletion class.
Limitations: Again only one opsin is lost rather than two, and the mouse retina has no fovea, so nothing about foveal cone topography — the structure that actually determines outcome in patients — can be modelled here.
Show evidence (1 reference)
PMID:28751656 SUPPORT Model Organism
"We generated an M-opsin knockout mouse (Opn1mw -/-) expressing only S-opsin as a model for human BCM."
States the model's design intent.
Absent or Non-Functional L and M Cone Photopigment rescues fidelity: moderate AAV5-delivered recombinant M-opsin restored M-cone function, establishing that an opsin-null cone remains competent to be rescued — the premise the entire gene-therapy strategy rests on.
Limitations: Rescue in a young mouse retina says nothing about the aged, largely non-waveguiding human foveal cone population that would actually be treated.
Show evidence (1 reference)
PMID:28751656 SUPPORT Model Organism
"Our study demonstrates that cones without M-opsin remain viable and respond to gene augmentation therapy, thereby providing proof-of-concept for cone function restoration in BCM patients."
The proof-of-concept result underpinning the investigational treatment.
{ }

Source YAML

click to show 
name: Blue Cone Monochromacy
creation_date: "2026-08-15T00:00:00Z"
category: Mendelian
parents:
- Cone dysfunction syndrome
- Inherited retinal disease
synonyms:
- BCM
- blue cone monochromatism
- S cone monochromacy
- S cone monochromatism
- X-linked incomplete achromatopsia
- X-chromosome-linked achromatopsia
disease_term:
  preferred_term: Blue Cone Monochromacy
  term:
    id: MONDO:0010563
    label: blue cone monochromacy
description: >-
  Blue cone monochromacy is an X-linked recessive cone dysfunction syndrome in
  which the long-wavelength (L, "red") and middle-wavelength (M, "green") cone
  photoreceptors are non-functional while short-wavelength (S, "blue") cones and
  rods are preserved. The lesion is at the OPN1LW/OPN1MW opsin gene array on
  Xq28, and its architecture is what makes the disease unusual: the two opsin
  genes sit head-to-tail with more than 98% sequence identity, and a single
  upstream locus control region (LCR) loops to one promoter at a time to enforce
  mutually exclusive expression of one opsin per cone. Because one LCR governs
  both genes, a single regulatory deletion silences the whole array — so a
  disorder that would otherwise require two independent hits is reachable in one
  step. The two commonest routes are exactly these: deletion of the LCR, and
  unequal crossing-over that collapses the array to a single gene which then
  carries the recurrent inactivating Cys203Arg substitution.

  Clinically this produces reduced but not absent visual acuity (roughly 20/60 to
  20/200), pendular nystagmus, photophobia, myopia, and colour discrimination
  that fails on the protan and deutan axes while retaining tritan discrimination
  — the preserved blue-yellow axis being the finding that separates it from
  complete achromatopsia at the bedside. The disorder was long taught as
  stationary, and the honest position is that this is only partly true: several
  families show psychophysical and structural progression, and progression rate
  tracks genotype, with large deletions degenerating faster than Cys203Arg. That
  genotype-dependence is not a curiosity but the central problem for the
  gene-therapy programmes now developing outcome measures for this disease, since
  it determines how wide the treatment window is and for whom.
inheritance:
- name: X-linked recessive
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >-
    Affected individuals are essentially all hemizygous males. Carrier females are
    usually clinically unaffected but are not biologically silent — see the carrier
    node in pathophysiology — and completely skewed X-inactivation can produce a
    manifesting female.
  evidence:
  - reference: PMID:22998501
    reference_title: Blue cone monochromatism in a female due to skewed X-inactivation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blue cone monochromatism (BCM) is a rare cone dystrophy with recessive
      X-linked inheritance and therefore diagnosed in males whereas females are
      clinically unaffected.
    explanation: >-
      States the inheritance mode and the sex distribution it produces.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.0
  notes: >-
    Approximately 1 in 100,000 worldwide. Note that this is a rate over the whole
    population; because the disorder is X-linked recessive, the rate among males is
    correspondingly higher.
  evidence:
  - reference: PMID:37001420
    reference_title: Blue cone monochromacy and gene therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is estimated that BCM affects approximately 1 in 100,000 people worldwide
    explanation: >-
      Source of the prevalence estimate.
pathophysiology:
- name: Loss of Function of the OPN1LW/OPN1MW Opsin Gene Array
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion. Both the L and M opsin genes on Xq28 must lose function;
    loss of only one produces ordinary red-green colour blindness, not this
    disorder. Two mutational routes dominate. The first is deletion of the locus
    control region 3.1-3.7 kb upstream of the array, which silences every gene
    downstream of it. The second is unequal homologous recombination that collapses
    the array to a single gene or a 5'L-M-3' hybrid, which then carries an
    inactivating point substitution — most often Cys203Arg, and less often
    Arg247Ter or Pro307Leu. High-resolution X-chromosome microarray has since
    resolved more complex rearrangements, including a founder allele combining a
    3-kb LCR deletion with insertion of an aberrant OPN1MW gene.
  genes:
  - preferred_term: OPN1LW
    term:
      id: hgnc:9936
      label: OPN1LW
  - preferred_term: OPN1MW
    term:
      id: hgnc:4206
      label: OPN1MW
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
  downstream:
  - target: Failure of Locus Control Region-Driven Opsin Expression
    causal_link_type: DIRECT
    description: >-
      Deletion of the locus control region removes the enhancer that both opsin
      promoters depend on.
  - target: Absent or Non-Functional L and M Cone Photopigment
    causal_link_type: DIRECT
    description: >-
      Inactivating coding substitutions in a collapsed single-gene array leave the
      cone without usable photopigment even when transcription proceeds.
  evidence:
  - reference: PMID:8213841
    reference_title: Genetic heterogeneity among blue-cone monochromats.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As observed in an earlier study, the rearrangements involve either deletion
      of a locus control region adjacent to the gene array or loss of function via
      homologous recombination and point mutation.
    explanation: >-
      Establishes the two dominant mutational routes that this node represents.
  - reference: PMID:8213841
    reference_title: Genetic heterogeneity among blue-cone monochromats.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two other point mutations were identified: (a) Arg247-to-Ter in one subject
      with a single red-pigment gene and (b) Pro307-to-Leu in one subject with a
      single 5' red-3' green hybrid gene.
    explanation: >-
      Documents the additional inactivating substitutions named in this node.
  - reference: PMID:26153062
    reference_title: >-
      High-resolution microarray analysis unravels complex Xq28 aberrations in
      patients and carriers affected by X-linked blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two families, we identified a novel founder mutation that consisted of a
      complex 3-kb deletion that embraced the cis-regulatory locus control region
      and insertion of an additional aberrant OPN1MW gene.
    explanation: >-
      Documents the complex rearrangement class that PCR-based testing missed.
  - reference: DOI:10.1126/science.2788922
    reference_title: >-
      Molecular Genetics of Human Blue Cone Monochromacy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One class arose from the wild type by a two-step pathway consisting of unequal
      homologous recombination and point mutation. The second class arose by
      nonhomologous deletion of genomic DNA adjacent to the red and green pigment
      gene cluster.
    explanation: >-
      The original two-class formulation of the mutational routes this node models.
- name: Failure of Locus Control Region-Driven Opsin Expression
  biological_scale: MOLECULAR
  description: >-
    The regulatory arm, and the reason a single deletion suffices. A locus control
    region between 3.1 and 3.7 kb upstream of the L opsin transcription start site
    is essential for expression of the adjacent visual pigment genes, and the
    mutually exclusive choice of one opsin per cone is set by competition between
    the two pigment promoters for pairing with that single LCR. Deleting it
    therefore does not silence one gene, it silences the array — converting what
    would need to be two independent inactivating events into one.
  genes:
  - preferred_term: OPN1LW
    term:
      id: hgnc:9936
      label: OPN1LW
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABSENT
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  downstream:
  - target: Absent or Non-Functional L and M Cone Photopigment
    causal_link_type: DIRECT
    description: >-
      With the enhancer gone, neither opsin promoter is transcribed in cones that
      would otherwise express L or M opsin.
  evidence:
  - reference: PMID:1524826
    reference_title: >-
      A locus control region adjacent to the human red and green visual pigment
      genes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      a region between 3.1 kb and 3.7 kb 5' of the red pigment gene transcription
      initiation site is essential for expression
    explanation: >-
      Transgenic-mouse mapping of the enhancer whose deletion causes the disease.
  - reference: PMID:1524826
    reference_title: >-
      A locus control region adjacent to the human red and green visual pigment
      genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deletion of sequences 5' of the human red and green pigment gene array
      results in blue cone monochromacy, a disorder in which both red and green
      cone function are absent.
    explanation: >-
      States the human genotype-phenotype relationship this node encodes.
  - reference: PMID:11773636
    reference_title: >-
      Role of a locus control region in the mutually exclusive expression of human
      red and green cone pigment genes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The results support a model in which the mutually exclusive expression of
      these genes in their respective cone types is controlled by competition
      between visual pigment promoters for pairing with the LCR
    explanation: >-
      Gives the regulatory model — one LCR shared by both promoters — that makes a
      single deletion sufficient.
  - reference: DOI:10.1126/science.2788922
    reference_title: >-
      Molecular Genetics of Human Blue Cone Monochromacy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These deletions define a 579-base pair region that is located 4 kilobases
      upstream of the red pigment gene and 43 kilobases upstream of the nearest green
      pigment gene; this 579-base pair region is essential for the activity of both
      pigment genes.
    explanation: >-
      The founding observation: patient deletions themselves delimited the essential
      shared regulatory element, before it was called a locus control region.
- name: Absent or Non-Functional L and M Cone Photopigment
  conforms_to: "phototransduction_cascade_dysfunction#Phototransduction Cascade Component Defect"
  biological_scale: CELLULAR
  description: >-
    The convergence point of both mutational routes. Cones that should express L or
    M opsin either make no opsin at all (deletion genotypes) or make an unstable,
    non-functional one (Cys203Arg disrupts a conserved disulfide bond required for
    correct folding of the seven-transmembrane opsin GPCR). Opsin is not only the
    light sensor but a structural requirement for building and maintaining the cone
    outer segment, so an opsin-null cone is compromised as a cell, not merely blind.
  cell_types:
  - preferred_term: L cone cell
    term:
      id: CL:0003048
      label: L cone cell
  - preferred_term: M cone cell
    term:
      id: CL:0003049
      label: M cone cell
  molecular_functions:
  - preferred_term: G protein-coupled photoreceptor activity
    term:
      id: GO:0008020
      label: G protein-coupled photoreceptor activity
    modifier: ABSENT
  biological_processes:
  - preferred_term: phototransduction
    term:
      id: GO:0007602
      label: phototransduction
    modifier: ABSENT
  downstream:
  - target: Cone Outer Segment Disruption and Progressive Foveal Cone Loss
    causal_link_type: DIRECT
    description: >-
      Absence of opsin destabilizes the outer segment and, over time, the cone
      itself.
  - target: Vision Mediated by Preserved S Cones and Rods
    causal_link_type: DIRECT
    description: >-
      With L and M cones silent, daylight vision falls back onto the S cones and
      partially desensitized rods.
  evidence:
  - reference: PMID:8213841
    reference_title: Genetic heterogeneity among blue-cone monochromats.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One inactivating mutation, Cys203-to-Arg, was found in 15 probands who carry
      single genes and in both visual pigment genes in one subject whose array has
      two genes.
    explanation: >-
      Establishes Cys203Arg as the dominant inactivating substitution.
  - reference: PMID:37001420
    reference_title: Blue cone monochromacy and gene therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Similar to rhodopsin in rods, cone opsins are crucial in both the maintenance
      and structural integrity of the cone outer segment, the light-sensing
      organelle of the cell.
    explanation: >-
      States the structural, not merely sensory, role of opsin that makes an
      opsin-null cone structurally vulnerable.
- name: Cone Outer Segment Disruption and Progressive Foveal Cone Loss
  biological_scale: TISSUE
  description: >-
    Foveal cones are structurally abnormal from early in life and decline further
    with age. Adaptive-optics imaging shows reduced total cone density with the
    majority of the remaining population non-waveguiding — that is, present as cells
    but not functioning as light guides. This is why the "stationary disorder"
    framing is only partly right: outer retinal changes are detectable on OCT with
    an age-related effect on foveal disease stage, and psychophysical progression
    has been demonstrated in individual families. Progression is genotype-dependent,
    with large deletions advancing faster than the Cys203Arg substitution.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: photoreceptor cell outer segment organization
    term:
      id: GO:0035845
      label: photoreceptor cell outer segment organization
    modifier: ABNORMAL
  locations:
  - preferred_term: fovea centralis
    term:
      id: UBERON:0001786
      label: fovea centralis
  evidence:
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AOSLO imaging showed reduced total cone density with majority of the
      population being non-waveguiding.
    explanation: >-
      Direct structural measurement of the residual foveal cone population.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Outer retinal changes were detectable by OCT with an age-related effect on
      the foveal disease stage.
    explanation: >-
      Supports an age-related structural component rather than a purely stationary
      disorder.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, foveal structural changes tend to progress faster in patients with
      large deletions as compared with the point mutation
    explanation: >-
      States the genotype-dependence of progression rate.
  - reference: PMID:36301530
    reference_title: Foveal Cone Structure in Patients With Blue Cone Monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mean total cone density for Cys203Arg patients was 16,664 ± 11,513 cones/mm2
      (n = 10), which is, on average, around 40% of normal.
    explanation: >-
      Quantifies the residual foveal cone population by adaptive-optics imaging.
  - reference: PMID:36301530
    reference_title: Foveal Cone Structure in Patients With Blue Cone Monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waveguiding cone density was 2073 ± 963 cones/mm2 (n = 9), which was consistent
      with published histological estimates of S-cone density in the normal eye.
    explanation: >-
      The load-bearing observation for this node: the cones that still waveguide are
      about as numerous as normal S cones, so the surviving L/M cones are present but
      optically silent rather than merely reduced in number.
- name: Vision Mediated by Preserved S Cones and Rods
  biological_scale: TISSUE
  description: >-
    What is left, and why the phenotype is what it is. S cones (OPN1SW, on
    chromosome 7) and rods are genetically untouched, so daylight vision is carried
    by the S-cone population — only a few percent of all cones, sparse in the fovea
    — together with rods operating partially desensitized in photopic conditions.
    That residual system explains the clinical picture directly: acuity is reduced
    but far from absent, colour discrimination survives on the tritan axis while
    failing on protan and deutan axes, and night vision is typically healthy. It is
    also the finding that separates this disorder from complete achromatopsia, where
    all cone signal is extinguished.
  cell_types:
  - preferred_term: S cone cell
    term:
      id: CL:0003050
      label: S cone cell
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  biological_processes:
  - preferred_term: visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: ABNORMAL
  evidence:
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most BCM patients have healthy night vision mediated by functioning rod
      photoreceptors.
    explanation: >-
      Establishes preserved rod-mediated scotopic vision.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Importantly, the daylight vision of BCM patients is mediated by the
      combination of short-wavelength-sensitive (S) cone photoreceptors and rod
      photoreceptors that function in a partially desensitized manner in a daylight
      environment
    explanation: >-
      States precisely which photoreceptor populations carry residual photopic
      vision.
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Affected males were shown to fail the protan and deutan axes, but retained
      good discrimination on the tritan axis of the MR test, a compelling evidence
      for residual colour vision in BCM.
    explanation: >-
      The psychophysical signature of preserved S-cone function.
  - reference: PMID:25909963
    reference_title: >-
      Blue cone monochromacy: visual function and efficacy outcome measures for
      clinical trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BCM rods continue to signal vision under conditions normally associated with
      daylight vision.
    explanation: >-
      Direct psychophysical demonstration that rods are carrying photopic vision,
      which is the claim this node makes.
  - reference: PMID:25909963
    reference_title: >-
      Blue cone monochromacy: visual function and efficacy outcome measures for
      clinical trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Short-wavelength (S-) sensitive cone function was normal or near normal in most
      patients.
    explanation: >-
      Confirms S-cone sparing quantitatively rather than by inference from the
      genotype.
- name: Carrier Female Cone Mosaic Disruption
  biological_scale: TISSUE
  description: >-
    Carrier females are described as unaffected, but they are not unaffected at the
    level of the retina. Random X-inactivation means roughly half of the cones fated
    to express L or M opsin instead express nothing, and imaging those retinas shows
    reduced cone density and disrupted mosaic organization relative to normal
    trichromats — evidence that opsin-null cones degenerate early rather than
    persisting silently. This is the cleanest natural experiment supporting the
    structural role of opsin asserted in the parent node, and it is the mechanism
    behind the rare manifesting female, in whom X-inactivation is completely skewed
    rather than random.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  evidence:
  - reference: PMID:20638402
    reference_title: >-
      Deletion of the X-linked opsin gene array locus control region (LCR) results
      in disruption of the cone mosaic.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On average, they had cone mosaics with reduced density and disrupted
      organization compared to normal trichromats.
    explanation: >-
      The imaging result in LCR-deletion carrier females.
  - reference: PMID:20638402
    reference_title: >-
      Deletion of the X-linked opsin gene array locus control region (LCR) results
      in disruption of the cone mosaic.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This suggests that the absence of opsin in a subset of cones results in their
      early degeneration, with X-inactivation the likely mechanism underlying
      phenotypic variability in BCM carriers.
    explanation: >-
      States both the degeneration inference and the X-inactivation mechanism.
  - reference: PMID:22998501
    reference_title: Blue cone monochromatism in a female due to skewed X-inactivation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis was genetically verified with the identification of one single
      red-green OPN1LW/MW hybrid gene harboring a point mutation c.607C>G,
      p.Cys203Arg that associates with BCM and in addition a completely biased
      X-inactivation in DNA isolated from full blood and buccal mucosa.
    explanation: >-
      Documents the completely skewed X-inactivation behind a manifesting female.
phenotypes:
- category: Ophthalmologic
  name: Severe Color Vision Defect with Preserved Tritan Discrimination
  frequency: OBLIGATE
  diagnostic: true
  description: >-
    Colour discrimination fails on the protan and deutan axes while tritan
    (blue-yellow) discrimination is retained. The retained axis is the
    diagnostically load-bearing part: it reflects surviving S-cone function and is
    what distinguishes this disorder from complete achromatopsia at the bedside.
  phenotype_term:
    preferred_term: Color vision defect
    term:
      id: HP:0000551
      label: Color vision defect
  evidence:
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Affected males were shown to fail the protan and deutan axes, but retained
      good discrimination on the tritan axis of the MR test, a compelling evidence
      for residual colour vision in BCM.
    explanation: >-
      Directly reports the axis-selective pattern.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Color vision was severely deficient. AOSLO imaging showed reduced total cone
      density with majority of the population being non-waveguiding.
    explanation: >-
      Confirms the severity of the colour deficit in a genotyped cohort.
- category: Ophthalmologic
  name: Reduced Visual Acuity
  frequency: OBLIGATE
  description: >-
    Acuity is reduced in all affected males, typically to around 20/60-20/200 —
    impaired but better than complete achromatopsia, because residual S-cone and rod
    input remains.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acuities were reduced in all affected males, and photopic b-wave was reduced
      by more than 90% in seven families.
    explanation: >-
      Establishes reduced acuity as universal across ten families.
- category: Ophthalmologic
  name: Nystagmus
  frequency: VERY_FREQUENT
  description: >-
    Pendular nystagmus, usually evident in infancy and often the presenting sign;
    amplitude commonly decreases with age without fully resolving.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
    onset:
      onset_category: INFANTILE
      notes: >-
        Typically evident by 3-6 months, when nystagmus and photophobia bring the
        child to attention. Infantile onset is a useful discriminator from the
        progressive cone dystrophies.
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blue cone monochromacy (BCM) is an X-linked ocular disease characterized by
      poor visual acuity, nystagmus, and photodysphoria in males with severely
      reduced color discrimination.
    explanation: >-
      Lists nystagmus among the defining clinical features.
- category: Ophthalmologic
  name: Photophobia
  frequency: VERY_FREQUENT
  description: >-
    Light sensitivity and glare intolerance, reported historically as photodysphoria
    and often managed with tinted lenses.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blue cone monochromacy (BCM) is an X-linked ocular disease characterized by
      poor visual acuity, nystagmus, and photodysphoria in males with severely
      reduced color discrimination.
    explanation: >-
      Photodysphoria is the historical term for the light sensitivity recorded here.
- category: Ophthalmologic
  name: Myopia
  frequency: FREQUENT
  description: >-
    Myopia, often significant. Useful in differential diagnosis: achromatopsia more
    typically runs hyperopic.
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: PMID:37001420
    reference_title: Blue cone monochromacy and gene therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BCM patients typically suffer from poor visual acuity, severely impaired color
      discrimination, myopia, and nystagmus.
    explanation: >-
      Lists myopia among the typical features.
- category: Electrophysiologic
  name: Severely Reduced Photopic Cone Electroretinogram
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    The L/M-cone-driven photopic response is severely reduced or undetectable while
    rod and mixed rod-cone responses are preserved. This dissociation — absent L/M
    signal with retained rod and S-cone signal — is the diagnostic hallmark.
    Reduction is not invariably complete: three of ten families in one series showed
    uncharacteristic relative preservation of the photopic b-wave, which is recorded
    here rather than rounded off.
  phenotype_term:
    preferred_term: Abnormal electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acuities were reduced in all affected males, and photopic b-wave was reduced
      by more than 90% in seven families.
    explanation: >-
      Quantifies the photopic ERG reduction.
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In three families, however, the photopic b-wave response showed
      uncharacteristic relative preservation of 30-80% (of the clinical low-normal
      value).
    explanation: >-
      The exception that keeps this phenotype from being curated as invariably
      absent.
- category: Ophthalmologic
  name: Progressive Macular Atrophy
  frequency: OCCASIONAL
  description: >-
    Macular atrophy develops in a subset and is the main late complication beyond
    the congenital deficit. It was seen in two of ten families in an early series
    while the remainder had a normal fundus, so it is genuinely a subset finding
    rather than an inevitable end state.
  phenotype_term:
    preferred_term: Macular degeneration
    term:
      id: HP:0000608
      label: Macular degeneration
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive macular atrophy was observed in affected members of two BCM
      families while the rest of the families presented with normal fundus.
    explanation: >-
      Gives both the finding and the denominator that justifies the OCCASIONAL band.
- category: Ophthalmologic
  name: Progressive Loss of Cone Function
  frequency: OCCASIONAL
  description: >-
    Although classically taught as stationary, psychophysical and clinical
    progression has been demonstrated in individual families, including one with a
    hybrid gene lacking exon 2. Recorded as a distinct phenotype because it changes
    counselling and, more consequentially, defines the therapeutic window for
    gene-replacement trials.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two families, psychophysical testing demonstrated evidence for progression
      of disease.
    explanation: >-
      Demonstrates progression psychophysically in a subset of families.
  - reference: PMID:19421413
    reference_title: >-
      Blue cone monochromacy: causative mutations and associated phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A novel mutation was detected in Family 2 that had a single hybrid gene
      lacking exon 2. This family presented clinical and psychophysical evidence of a
      slowly progressive phenotype.
    explanation: >-
      Ties a progressive phenotype to a specific genotype, supporting genotype
      dependence.
genetic:
- name: OPN1LW/OPN1MW opsin gene array
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: OPN1LW
    term:
      id: hgnc:9936
      label: OPN1LW
  inheritance:
  - name: X-linked recessive
  notes: >-
    Disease requires loss of function of both the L and M opsin genes. Loss of just
    one produces ordinary red-green colour vision deficiency. The locus is
    intrinsically recombinogenic — two near-identical genes in tandem — which is why
    unequal crossing-over and gene conversion recur as mutational mechanisms rather
    than being incidental.
  evidence:
  - reference: PMID:26153062
    reference_title: >-
      High-resolution microarray analysis unravels complex Xq28 aberrations in
      patients and carriers affected by X-linked blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blue cone monochromacy (BCM) is an X-linked condition caused by a
      loss-of-function of both the OPN1LW and OPN1MW opsin genes.
    explanation: >-
      States the two-gene loss-of-function requirement.
  - reference: PMID:26153062
    reference_title: >-
      High-resolution microarray analysis unravels complex Xq28 aberrations in
      patients and carriers affected by X-linked blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cone opsin gene cluster is composed of 2-9 paralogs with 99.8% sequence
      homology and is susceptible to deletions, duplications, and mutations.
    explanation: >-
      Explains the locus architecture that makes recurrent rearrangement the
      dominant mutational mechanism.
- name: OPN1MW
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: OPN1MW
    term:
      id: hgnc:4206
      label: OPN1MW
  inheritance:
  - name: X-linked recessive
  notes: >-
    The M-opsin gene of the tandem array. Curated separately from OPN1LW because
    genotypes differ in which array member survives: some patients retain a single L
    gene, some a 5'L-M-3' hybrid, and at least one reported family lost the complete
    green gene with no coding or LCR change detectable in the red gene.
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In one family no mutation was found in the exons of the red gene or the locus
      control region but showed loss of the complete green gene.
    explanation: >-
      Documents the genotype in which the M gene is the demonstrable lesion.
- name: Locus control region deletion
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: OPN1LW
    term:
      id: hgnc:9936
      label: OPN1LW
  inheritance:
  - name: X-linked recessive
  notes: >-
    Deletion of the upstream enhancer is a variant class in its own right, and the
    dominant one: 90% of structural variants found in molecularly confirmed families
    remove it. Curated separately from coding-sequence lesions because the
    consequence is regulatory silencing of an intact gene array rather than loss of a
    functional protein product, which is why it has its own pathophysiology node.
    Deletion mapping in patients has narrowed the minimal functional extent of the
    element to 358 bp.
  evidence:
  - reference: PMID:35759666
    reference_title: >-
      The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene
      cluster on Xq28 underlying blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, 90% of SVs encompass the upstream locus control region, an essential
      enhancer element. Its minimal functional extent based on deletion mapping in
      patients was refined to 358 bp.
    explanation: >-
      Quantifies how often the enhancer is involved and gives the patient-derived
      minimal functional extent.
- name: Structural variant landscape of the OPN1LW/OPN1MW cluster
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: OPN1MW
    term:
      id: hgnc:4206
      label: OPN1MW
  notes: >-
    About a third of molecularly confirmed families carry a structural variant, and
    the striking negative finding is that there is no region of overlap among them —
    which is why this disorder cannot be reduced to a single recurrent deletion and
    why testing has to resolve breakpoints rather than assay one interval. Large
    pre-existing gene arrays appear predisposed to generating these variants, which
    fits the recombinogenic architecture described elsewhere in this entry.
  evidence:
  - reference: PMID:35759666
    reference_title: >-
      The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene
      cluster on Xq28 underlying blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found that about one-third (n = 73) of the 213 molecularly confirmed BCM
      families carry an SV, most commonly deletions restricted to the OPN1LW/OPN1MW
      gene cluster.
    explanation: >-
      Quantifies the share of families with a structural variant.
  - reference: PMID:35759666
    reference_title: >-
      The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene
      cluster on Xq28 underlying blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, 42 distinct SVs were identified, including 40 previously unreported
      SVs, thereby quadrupling the number of precisely mapped SVs underlying BCM.
      Notably, there was no "region of overlap" among these SVs.
    explanation: >-
      Establishes both the diversity of variants and the absence of a common
      minimal region.
  - reference: PMID:35759666
    reference_title: >-
      The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene
      cluster on Xq28 underlying blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using parsimonious assumptions, we reconstructed the composition and copy
      number of the OPN1LW/OPN1MW gene cluster prior to the mutation event and found
      evidence that large gene arrays may be predisposed to the occurrence of SVs at
      this locus.
    explanation: >-
      Links array size to structural-variant susceptibility, supporting the
      architectural argument.
- name: GPR143
  association: Disease-associated
  relationship_type: MODIFIER
  gene_term:
    preferred_term: GPR143
    term:
      id: hgnc:20145
      label: GPR143
  notes: >-
    Recorded from a single patient in whom a GPR143 splicing variant co-occurred with
    OPN1LW/OPN1MW lesions and produced foveal hypoplasia — a feature otherwise
    characteristic of achromatopsia rather than this disorder. Curated as a modifier
    on one report, not as an established modifier gene.
  evidence:
  - reference: PMID:34445325
    reference_title: >-
      Blue Cone Monochromatism with Foveal Hypoplasia Caused by the Concomitant
      Effect of Variants in OPN1LW/OPN1MW and GPR143 Genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To our knowledge, this is the first case of foveal hypoplasia in a BCM patient
      and of mild clinical affection in a female carrier caused by the concomitant
      effect of variants in OPN1LW/OPN1MW and GPR143 genes, thus as the result of the
      simultaneous action of two independent genetic defects.
    explanation: >-
      Single-case evidence for a second-locus modifier effect; PARTIAL because it
      rests on one family.
- name: Cys203Arg recurrent inactivating substitution
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: OPN1LW
    term:
      id: hgnc:9936
      label: OPN1LW
  notes: >-
    The single most common inactivating point substitution. Its epidemiology is
    unusual and mechanistically informative: it is present at low frequency in
    control chromosomes, which means the population carries a standing reservoir of
    Cys203Arg alleles that unequal recombination or gene conversion can convert into
    a disease genotype in one further step. That is a recurrence mechanism, not a
    founder effect.
  evidence:
  - reference: PMID:8213841
    reference_title: Genetic heterogeneity among blue-cone monochromats.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This mutation was also found in at least one of the visual pigment genes in 1
      subject whose array has multiple genes and in 2 of 321 control subjects,
      suggesting that preexisting Cys203-to-Arg mutations constitute a reservoir of
      chromosomes that are predisposed to generate blue-cone-monochromat genotypes
      by unequal homologous recombination and/or gene conversion.
    explanation: >-
      States the reservoir hypothesis that explains recurrence of this allele.
diagnosis:
- name: Full-Field Electroretinography
  description: >-
    The key functional test. Rod-specific and mixed rod-cone responses are normal or
    near-normal while the L/M-cone-driven photopic response is severely reduced or
    absent, and S-cone-isolating stimuli still elicit a response. It is that
    dissociation, not the absolute amplitudes, that makes the diagnosis.
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acuities were reduced in all affected males, and photopic b-wave was reduced
      by more than 90% in seven families.
    explanation: >-
      Quantifies the photopic reduction that anchors the ERG diagnosis.
  - reference: PMID:38871951
    reference_title: >-
      S-cone contribution to oscillatory potentials in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aim of this exploratory study is to investigate the role of S-cones in
      oscillatory potentials (OPs) generation by individuals with blue-cone
      monochromacy (BCM), retaining S-cones, and achromatopsia (ACHM), lacking cone
      functions.
    explanation: >-
      Frames the retained-S-cone versus absent-cone-function contrast that the ERG
      exploits; PARTIAL because the study itself examines an ancillary
      oscillatory-potential signature rather than validating the diagnostic test.
- name: Colour Vision Testing
  description: >-
    Farnsworth D-15 gives protan-like arrangements. The Mollon-Reffin Minimal test
    is particularly useful because it resolves the retained tritan axis, and HRR
    plates detect the same residual discrimination.
  evidence:
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, we have demonstrated that the Mollon-Reffin (MR) Minimal test is
      a useful colour-discrimination test to aid in the diagnosis of BCM.
    explanation: >-
      Identifies the colour test with the best discriminating value here.
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have confirmed the reported finding of protan-like D-15 arrangements of
      patients with BCM.
    explanation: >-
      Documents the D-15 pattern.
  - reference: PMID:36692456
    reference_title: >-
      Color Vision in Blue Cone Monochromacy: Outcome Measures for a Clinical Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With D-15, there was protan-deutan confusion and no bimodal tendency.
    explanation: >-
      Characterizes the D-15 result pattern specific to this disorder.
  - reference: PMID:36692456
    reference_title: >-
      Color Vision in Blue Cone Monochromacy: Outcome Measures for a Clinical Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given understanding of advantages, disadvantages, and complexities of
      interpretation of results, both an arrangement test and CAD should be useful
      monitors of color vision through a clinical trial in BCM.
    explanation: >-
      Supports the choice of colour tests, and their role as trial endpoints.
- name: Molecular Testing of the Xq28 Opsin Array
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Standard short-read exome pipelines are unreliable at this locus because the
    paralogs are about 99.8% identical, so a negative exome does not exclude the
    diagnosis. Targeted approaches — long-range PCR, Southern blot, and
    high-resolution X-chromosome microarray — are required, and microarray in
    particular resolves alterations that PCR-based testing leaves undetermined in
    around 10% of patients and extends testing to female carriers.
  evidence:
  - reference: PMID:26153062
    reference_title: >-
      High-resolution microarray analysis unravels complex Xq28 aberrations in
      patients and carriers affected by X-linked blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Current diagnostic tests employ polymerase chain reaction (PCR)-based
      technologies; however, alterations remain undetermined in 10% of patients.
      Furthermore, carrier testing in females is limited or unavailable.
    explanation: >-
      States the diagnostic gap that motivates microarray-based testing.
  - reference: PMID:26153062
    reference_title: >-
      High-resolution microarray analysis unravels complex Xq28 aberrations in
      patients and carriers affected by X-linked blue cone monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathogenic alterations were revealed in all probands, characterized by
      sequencing of the breakpoint junctions and quantitative real-time PCR.
    explanation: >-
      Demonstrates the diagnostic yield of the microarray approach.
differential_diagnoses:
- name: Achromatopsia
  description: >-
    Autosomal recessive complete cone dysfunction (CNGA3, CNGB3, GNAT2, PDE6C,
    PDE6H, ATF6) affecting all three cone classes rather than only L and M. It is
    the principal differential, and the electroretinogram is what settles it.
  disease_term:
    preferred_term: achromatopsia
    term:
      id: MONDO:0018852
      label: achromatopsia
  distinguishing_features:
  - All cone signal extinguished on ERG, including S-cone-isolating stimuli
  - No retained tritan axis on colour testing
  - Typically worse visual acuity
  - Hyperopia more typical than myopia
  - Autosomal recessive rather than X-linked inheritance
  evidence:
  - reference: PMID:38871951
    reference_title: >-
      S-cone contribution to oscillatory potentials in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aim of this exploratory study is to investigate the role of S-cones in
      oscillatory potentials (OPs) generation by individuals with blue-cone
      monochromacy (BCM), retaining S-cones, and achromatopsia (ACHM), lacking cone
      functions.
    explanation: >-
      States the retained-S-cone versus absent-cone-function contrast that separates
      the two disorders.
  - reference: PMID:36186895
    reference_title: >-
      Comparing Retinal Structure in Patients with Achromatopsia and Blue Cone
      Monochromacy Using OCT.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Foveal hypoplasia was significantly more prevalent in ACHM than in BCM
      (p<0.001).
    explanation: >-
      Quantifies the foveal-hypoplasia difference that helps separate the two on OCT.
- name: X-linked cone dystrophy
  description: >-
    Missense variants in the same L/M opsin genes can produce X-linked cone
    dystrophy or high myopia with abnormal cone function rather than this disorder,
    so the same locus spans a phenotypic range and genotype alone does not settle
    the diagnosis.
  distinguishing_features:
  - Progressive cone degeneration rather than a predominantly congenital deficit
  - A different pattern of L/M opsin missense alleles at the same locus
  evidence:
  - reference: PMID:37001420
    reference_title: Blue cone monochromacy and gene therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      X-linked retinal diseases resulting from mutations in the L- (OPN1LW, OMIM
      *300822) and M- (OPN1MW, OMIM *300821) opsin gene cluster are associated with
      a wide range of visual defects, including red/green color vision deficiency,
      X-linked cone dystrophy/dysfunction, high myopia with abnormal cone function,
      and blue cone monochromacy (BCM)
    explanation: >-
      Establishes that the same locus produces a spectrum of distinct diagnoses.
treatments:
- name: Tinted Lenses and Low Vision Aids
  description: >-
    The whole of current management. Tinted lenses reduce photophobia and improve
    contrast; low-vision aids address the acuity deficit. Nothing available today
    modifies the underlying disease.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There are currently no treatments for BCM, and management of the disease is
      limited to the use of tinted lenses and low vision aids.
    explanation: >-
      States both the absence of disease-modifying therapy and the content of
      current management.
- name: AAV-Mediated L-Opsin Gene Augmentation (investigational)
  description: >-
    The therapeutic strategy in development: deliver a functional L-opsin gene to
    residual L/M cones by adeno-associated virus. It is investigational, not
    approved, and is recorded here as a research programme rather than a treatment
    option. Its central design problem follows directly from the pathophysiology
    above — the residual cones are largely non-waveguiding and decline with age, so
    the therapeutic window is bounded and strongly age-dependent. Genotype governs
    the rate of progression rather than the width of the window: the two mouse models
    compared so far showed similar windows despite different genotypes. Much of the recent
    clinical literature is accordingly about building outcome measures sensitive
    enough to detect an L-cone-specific gain. Route of delivery is itself a design
    constraint here: subretinal injection risks the very foveal structure that is
    the therapeutic target, which is why an intravitreal vector was developed.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Absent or Non-Functional L and M Cone Photopigment
    treatment_effect: RESTORES
    description: >-
      Gene augmentation aims to restore L-opsin expression in surviving cones; it
      cannot recover cones already lost, which is why the timing question is
      central.
    evidence:
    - reference: PMID:39408969
      reference_title: >-
        Evaluation of Retinal Structure and Visual Function in Blue Cone
        Monochromacy to Develop Clinical Endpoints for L-opsin Gene Therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        L-cone opsin expression by gene therapy is a promising treatment for blue
        cone monochromacy (BCM) caused by congenital lack of long- and
        middle-wavelength-sensitive (L/M) cone function.
      explanation: >-
        States the therapeutic rationale and its molecular target.
  evidence:
  - reference: PMID:36932675
    reference_title: >-
      Preclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector
      for the treatment of blue cone monochromacy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      A single IVT administration dose of ADVM-062 effectively transduced gerbil
      cone photoreceptors and produced a de novo response to long-wavelength
      stimuli.
    explanation: >-
      Preclinical proof that an intravitreally delivered L-opsin vector produces a
      new long-wavelength response, in an animal whose cone-rich retina naturally
      lacks L-opsin.
  - reference: PMID:36932675
    reference_title: >-
      Preclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector
      for the treatment of blue cone monochromacy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, most experimental ocular gene therapies utilize subretinal vector
      injection which would pose a risk to the fragile central retinal structure of
      BCM patients.
    explanation: >-
      Supports the delivery-route constraint stated in the description.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study developed and evaluated specialized outcomes that will be needed
      for the determination of efficacy and safety in human clinical trials.
    explanation: >-
      Confirms that human trials are prospective rather than completed, which is why
      this is curated as investigational.
  - reference: PMID:40297680
    reference_title: >-
      Molecular Mechanisms Limiting the Therapeutic Window of AAV Gene Therapy in
      Mouse Models of Blue Cone Monochromacy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      While both DKO and C198R models showed similar therapeutic windows and rescue
      longevity, treatment efficacy decreased markedly in older mutant mice.
    explanation: >-
      The evidence behind the bounded-therapeutic-window claim in the description.
      Note it also qualifies it: in these two models the window was similar across
      genotypes, so the age dependence is better supported than the genotype
      dependence.
  - reference: PMID:33344057
    reference_title: >-
      Reading Performance in Blue Cone Monochromacy: Defining an Outcome Measure for
      a Clinical Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MNREAD measures of reading performance in patients with BCM would be a worthy
      and robust secondary outcome in a clinical trial protocol, given its dual
      purpose of quantifying macular vision and addressing an important quality of
      life issue.
    explanation: >-
      Part of the outcome-measure groundwork that has to exist before a trial can
      run, which is why this treatment is curated as investigational.
animal_models:
- name: Opn1mw C198R knock-in mouse
  species: Mouse
  genotype: Opn1mw C198R knock-in (murine equivalent of human OPN1MW Cys203Arg)
  publication: PMID:41941983
  description: >-
    The mouse counterpart of the commonest human missense allele. Because murine
    M-opsin is five residues shorter at the amino terminus, the equivalent
    substitution is numbered C198R.
  modeled_mechanisms:
  - target: Absent or Non-Functional L and M Cone Photopigment
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Diminished M-opsin expression with mislocalization, and loss of cone outer
      segments in M-cone photoreceptors — the structural consequence this node
      asserts.
    limitations: >-
      Mouse has no L-opsin at all, so the model reproduces only the M-cone half of
      the human two-opsin lesion; and in vitro the mutant aggregates while in vivo it
      does not, so cell-culture results from this allele overstate the in vivo
      severity.
    evidence:
    - reference: PMID:41941983
      reference_title: Molecular and cellular impact of a C203R/C198R M-opsin mutation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The mutation diminished the expression of M-opsin with some apparent
        mislocalization of the cone opsin without aggregation, which resulted in the
        loss of cone outer segments in M-cone photoreceptor cells.
      explanation: >-
        The in vivo structural result linking the allele to outer-segment loss.
  - target: Cone Outer Segment Disruption and Progressive Foveal Cone Loss
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces outer-segment loss but not cone death: mutant cones remained viable
      to six months in both hemizygous and homozygous animals, and the authors
      contrast this explicitly with the toxic-aggregate mechanism of rhodopsin
      mutants in retinitis pigmentosa.
    limitations: >-
      Six months of mouse life cannot address decades of human disease, so a viable
      cone at six months does not establish that the human Cys203Arg cone survives —
      it establishes that a toxic-aggregate death mechanism is not operating early.
      This is why the entry treats slow Cys203Arg progression as observed rather than
      mechanistically explained.
    evidence:
    - reference: PMID:41941983
      reference_title: Molecular and cellular impact of a C203R/C198R M-opsin mutation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Despite the loss of cone outer segments, cone photoreceptor cells remained
        viable, even up to 6 months of age in hemizygous and homozygous mutant mice.
      explanation: >-
        The dissociation between outer-segment loss and cone survival.
    - reference: PMID:41941983
      reference_title: Molecular and cellular impact of a C203R/C198R M-opsin mutation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Thus, in contrast to rhodopsin mutants, the M-opsin mutant does not appear to
        form toxic aggregates that cause cone photoreceptor cell death.
      explanation: >-
        States the negative mechanistic conclusion that distinguishes this from the
        rhodopsin misfolding diseases.
- name: Opn1mw knockout mouse
  species: Mouse
  genotype: Opn1mw -/- (M-opsin knockout, expressing only S-opsin)
  publication: PMID:28751656
  description: >-
    An opsin-null model built explicitly as the mouse stand-in for the human
    deletion genotype, and the vehicle for the first cone-rescue proof of concept.
  modeled_mechanisms:
  - target: Absent or Non-Functional L and M Cone Photopigment
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Cones lacking M-opsin, the null counterpart of the human deletion class.
    limitations: >-
      Again only one opsin is lost rather than two, and the mouse retina has no
      fovea, so nothing about foveal cone topography — the structure that actually
      determines outcome in patients — can be modelled here.
    evidence:
    - reference: PMID:28751656
      reference_title: >-
        Gene-based Therapy in a Mouse Model of Blue Cone Monochromacy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We generated an M-opsin knockout mouse (Opn1mw -/-) expressing only S-opsin
        as a model for human BCM.
      explanation: >-
        States the model's design intent.
  - target: Absent or Non-Functional L and M Cone Photopigment
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      AAV5-delivered recombinant M-opsin restored M-cone function, establishing that
      an opsin-null cone remains competent to be rescued — the premise the entire
      gene-therapy strategy rests on.
    limitations: >-
      Rescue in a young mouse retina says nothing about the aged, largely
      non-waveguiding human foveal cone population that would actually be treated.
    evidence:
    - reference: PMID:28751656
      reference_title: >-
        Gene-based Therapy in a Mouse Model of Blue Cone Monochromacy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Our study demonstrates that cones without M-opsin remain viable and respond
        to gene augmentation therapy, thereby providing proof-of-concept for cone
        function restoration in BCM patients.
      explanation: >-
        The proof-of-concept result underpinning the investigational treatment.
discussions:
- discussion_id: bcm_stationary_versus_progressive
  kind: CONTROVERSY
  prompt: >-
    Is blue cone monochromacy a stationary cone dysfunction syndrome or a slowly
    progressive dystrophy, and how much of the disagreement is explained by genotype
    rather than by measurement sensitivity?
  attaches_to:
  - pathophysiology#Cone Outer Segment Disruption and Progressive Foveal Cone Loss
  - phenotypes#Progressive Loss of Cone Function
  rationale: >-
    The disorder is classified among the stationary cone dysfunction syndromes, and
    many families do appear stable. But progression has been demonstrated
    psychophysically in individual families, macular atrophy develops in a subset,
    OCT shows an age-related effect on foveal disease stage, and the rate differs
    between large-deletion and Cys203Arg genotypes. Curating this as simply
    "stationary" would be wrong, and curating it as simply "progressive" would
    overstate what is shown for most patients. The unresolved part is whether the
    apparently stable majority are genuinely stable or merely followed for too short
    a time with insufficiently sensitive measures — which matters directly, because
    a bounded therapeutic window is the main design constraint on the gene therapy
    programmes.
  proposed_experiments:
  - experiment_id: bcm_longitudinal_genotype_stratified_aoslo
    name: Longitudinal genotype-stratified AOSLO and microperimetry cohort
    description: >-
      Follow LCR-deletion and Cys203Arg cohorts prospectively with adaptive-optics
      cone density, OCT outer nuclear layer thickness, and dark-adapted red
      microperimetry, to establish whether the stable-appearing majority show
      measurable decline on sensitive endpoints and to quantify the window per
      genotype.
  evidence:
  - reference: PMID:15094734
    reference_title: >-
      Blue cone monochromatism: a phenotype and genotype assessment with evidence of
      progressive loss of cone function in older individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two families, psychophysical testing demonstrated evidence for progression
      of disease.
    explanation: >-
      Evidence for the progressive side of the question.
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive macular atrophy was observed in affected members of two BCM
      families while the rest of the families presented with normal fundus.
    explanation: >-
      Shows that progression is a subset finding, which is the other side of the
      controversy.
  - reference: PMID:41941983
    reference_title: Molecular and cellular impact of a C203R/C198R M-opsin mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Despite the loss of cone outer segments, cone photoreceptor cells remained
      viable, even up to 6 months of age in hemizygous and homozygous mutant mice.
    explanation: >-
      Model-organism evidence bearing on the stationary side: in the allele
      equivalent to Cys203Arg, the cone loses its outer segment without dying, which
      is a mechanism for structural change without progressive cell loss. PARTIAL
      because six mouse months cannot speak to decades of human disease.
- discussion_id: bcm_genotype_phenotype_correlation
  kind: OPEN_QUESTION
  prompt: >-
    Does genotype at the opsin array predict the clinical phenotype, given that one
    series found no genotype-phenotype association while later structural work found
    deletion genotypes progress faster than Cys203Arg?
  attaches_to:
  - pathophysiology#Loss of Function of the OPN1LW/OPN1MW Opsin Gene Array
  rationale: >-
    These findings are not straightforwardly contradictory — the earlier study
    assessed cross-sectional clinical and electrophysiological phenotype, the later
    work assessed rate of structural change — but they are routinely quoted against
    each other. Resolving which phenotypic dimensions genotype predicts (baseline
    severity versus rate of decline) is what a counselling statement or a trial
    stratification would actually need.
  evidence:
  - reference: PMID:10982039
    reference_title: >-
      Spectrum of color gene deletions and phenotype in patients with blue cone
      monochromacy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No association was observed between the phenotypes and genotypes in these
      families.
    explanation: >-
      The negative cross-sectional finding.
  - reference: PMID:39408969
    reference_title: >-
      Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy
      to Develop Clinical Endpoints for L-opsin Gene Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, foveal structural changes tend to progress faster in patients with
      large deletions as compared with the point mutation
    explanation: >-
      The positive longitudinal-structural finding on the other side.
  - reference: PMID:35400991
    reference_title: >-
      Relatively mild blue cone monochromacy phenotype caused by various haplotypes
      in the L- and M-cone opsin genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blue cone monochromacy (BCM) is an X-linked retinopathy caused by mutations in
      the red and green cone opsin genes. The aim of this study was to establish the
      clinical, genetic, and electrophysiological characteristics of a specific form
      of BCM.
    explanation: >-
      Cited as a study framed around a haplotype-defined milder form, which is
      evidence that genotype tracks severity in at least some direction; PARTIAL
      because only the framing, not a quantified correlation, is quotable from the
      cached abstract.
notes: >-
  Relationship to Achromatopsia. This entry deliberately overlaps with, but is
  distinct from, the existing Achromatopsia entry. Achromatopsia is autosomal
  recessive and abolishes all three cone classes; this disorder is X-linked and
  spares S cones. The Achromatopsia entry already lists blue-cone monochromatism as
  a differential; this entry is the reciprocal, curated on its own genetics and
  mechanism rather than as a variant of achromatopsia. The MONDO definition
  describes it as an incomplete form of achromatopsia, which is a reasonable
  classification statement but should not be read as implying shared
  pathophysiology — the causal genes and the cone populations involved differ.

  Ontology limits worth recording. UBERON has no term for the S-cone-sparse central
  zone of the fovea, and CL distinguishes L, M and S cone cells but not the
  hybrid-opsin-expressing cones that many patients actually carry. Neither gap was
  worked around by picking a broader term and describing something narrower in
  prose.

  One reference could not be cited. `DOI:10.1186/s12881-018-0623-8` reports a
  73,128 bp de novo deletion in sporadic disease and would have been the natural
  citation for de novo occurrence, but the cached record carries
  `content_type: unavailable` — metadata only, no abstract text — so there is no
  quotable snippet. The claim is therefore omitted rather than cited to a record
  that cannot support it, and the cache file has been dropped rather than left
  stranded in the commit.

  Two ontology suggestions in the deep-research report were wrong and were not
  used: UBERON:0001782 was suggested for fovea centralis but is the pigmented layer
  of the retina (the correct term is UBERON:0001786), and HP:0000640 was suggested
  for nystagmus (the correct term is HP:0000639). Both were caught by checking
  against the term caches, not by the report's own reference validation, which
  checks citations only.
references:
- reference: DOI:10.1126/science.2788922
  title: Molecular Genetics of Human Blue Cone Monochromacy
- reference: PMID:1524826
  title: A locus control region adjacent to the human red and green visual pigment genes.
- reference: PMID:8213841
  title: Genetic heterogeneity among blue-cone monochromats.
- reference: PMID:10982039
  title: >-
    Spectrum of color gene deletions and phenotype in patients with blue cone
    monochromacy.
- reference: PMID:11773636
  title: >-
    Role of a locus control region in the mutually exclusive expression of human red
    and green cone pigment genes.
- reference: PMID:15094734
  title: >-
    Blue cone monochromatism: a phenotype and genotype assessment with evidence of
    progressive loss of cone function in older individuals.
- reference: PMID:19421413
  title: >-
    Blue cone monochromacy: causative mutations and associated phenotypes.
- reference: PMID:20638402
  title: >-
    Deletion of the X-linked opsin gene array locus control region (LCR) results in
    disruption of the cone mosaic.
- reference: PMID:22998501
  title: Blue cone monochromatism in a female due to skewed X-inactivation.
- reference: PMID:26153062
  title: >-
    High-resolution microarray analysis unravels complex Xq28 aberrations in patients
    and carriers affected by X-linked blue cone monochromacy.
- reference: PMID:35759666
  title: >-
    The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene
    cluster on Xq28 underlying blue cone monochromacy.
- reference: PMID:36301530
  title: Foveal Cone Structure in Patients With Blue Cone Monochromacy.
- reference: PMID:37001420
  title: Blue cone monochromacy and gene therapy.
- reference: PMID:39408969
  title: >-
    Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy to
    Develop Clinical Endpoints for L-opsin Gene Therapy.
- reference: PMID:41941983
  title: Molecular and cellular impact of a C203R/C198R M-opsin mutation.
📚

References & Deep Research

References

15
DOI:10.1126/science.2788922
Molecular Genetics of Human Blue Cone Monochromacy
No top-level findings curated for this source.
PMID:1524826
A locus control region adjacent to the human red and green visual pigment genes.
No top-level findings curated for this source.
PMID:8213841
Genetic heterogeneity among blue-cone monochromats.
No top-level findings curated for this source.
PMID:10982039
Spectrum of color gene deletions and phenotype in patients with blue cone monochromacy.
No top-level findings curated for this source.
PMID:11773636
Role of a locus control region in the mutually exclusive expression of human red and green cone pigment genes.
No top-level findings curated for this source.
PMID:15094734
Blue cone monochromatism: a phenotype and genotype assessment with evidence of progressive loss of cone function in older individuals.
No top-level findings curated for this source.
PMID:19421413
Blue cone monochromacy: causative mutations and associated phenotypes.
No top-level findings curated for this source.
PMID:20638402
Deletion of the X-linked opsin gene array locus control region (LCR) results in disruption of the cone mosaic.
No top-level findings curated for this source.
PMID:22998501
Blue cone monochromatism in a female due to skewed X-inactivation.
No top-level findings curated for this source.
PMID:26153062
High-resolution microarray analysis unravels complex Xq28 aberrations in patients and carriers affected by X-linked blue cone monochromacy.
No top-level findings curated for this source.
PMID:35759666
The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene cluster on Xq28 underlying blue cone monochromacy.
No top-level findings curated for this source.
PMID:36301530
Foveal Cone Structure in Patients With Blue Cone Monochromacy.
No top-level findings curated for this source.
PMID:37001420
Blue cone monochromacy and gene therapy.
No top-level findings curated for this source.
PMID:39408969
Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy to Develop Clinical Endpoints for L-opsin Gene Therapy.
No top-level findings curated for this source.
PMID:41941983
Molecular and cellular impact of a C203R/C198R M-opsin mutation.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Blue Cone Monochromacy: Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 50 citations 2026-08-15T19:16:25.435996

Blue Cone Monochromacy: Comprehensive Research Report

1. Disease Information

Overview

Blue cone monochromacy (BCM) is a rare, congenital, X-linked recessive retinal disorder characterized by absent or severely reduced function of the long-wavelength (L, "red") and middle-wavelength (M, "green") sensitive cone photoreceptors, with preserved function of short-wavelength (S, "blue") cones and rods. It is sometimes classified as an "incomplete" or "atypical" form of achromatopsia, or as X-linked congenital cone dysfunction. Patients typically present at birth or in early infancy with poor visual acuity, pendular nystagmus, photophobia, myopia, and severely impaired color discrimination limited largely to the blue range of the spectrum (Wikipedia; Vision Research review).

Key Identifiers

  • OMIM: #303700 (Blue Cone Monochromacy; BCM) — phenotype entry; causal genes OPN1LW (300822), OPN1MW (300821), and the locus control region (LCR; *300824) (OMIM 303700; OMIM 300822; OMIM 300821)
  • Orphanet (ORPHA): ORPHA:16 — "Blue cone monochromatism," prevalence class 1–9/100,000, X-linked recessive, infancy onset (Orphanet)
  • MONDO: MONDO:0010563
  • ICD-10-CM: H53.5x (Color vision deficiencies); frequently cross-coded/grouped with H53.51 (Achromatopsia) since ICD-10-CM has no dedicated BCM code
  • MeSH/GARD synonym entry: "Cone monochromatism" (NIH GARD) (GARD)
  • GeneReviews-adjacent resource: Achromatopsia GeneReviews chapter discusses BCM in differential diagnosis (NCBI Bookshelf NBK1418)

Synonyms and Alternative Names

  • X-linked incomplete achromatopsia / atypical achromatopsia
  • S-cone monochromacy (informal; technically S-cones and rods are the only functioning photoreceptors)
  • X-linked cone dysfunction syndrome
  • Pi-1 pigment deficiency / "blue monochromatism" (historical terms)

The condition was first clinically described by J. Huddart in 1777, and typical vs. "atypical" (incomplete) achromatopsia was distinguished by Sloan in 1942 based on inheritance pattern; the molecular genetic basis at the OPN1LW/OPN1MW locus was established by Nathans and colleagues in 1989 and 1993 (Wikipedia; Nathans et al., Science 1989).

Data Source Type

Information is derived predominantly from aggregated disease-level resources: peer-reviewed case series and genotype-phenotype cohort studies (tertiary academic centers, e.g., University of Pennsylvania Center for Hereditary Retinal Degenerations), Orphanet/OMIM curated summaries, and molecular genetics literature — rather than large-scale EHR datasets, reflecting BCM's rarity (~1/100,000).

2. Etiology

Disease Causal Factors

BCM is caused exclusively by genetic mechanisms — combined loss of function of both the OPN1LW and OPN1MW genes at Xq28. There are no known environmental, infectious, or acquired causes; it is a purely Mendelian, monogenic (locus-level) disorder. Three principal molecular mechanisms account for essentially all cases (Gardner et al., Mol Vis 2009, PMID:19421413):

  1. Locus control region (LCR) deletions (~40% of families): Deletion of the LCR, located 3.1–3.7 kb upstream of the OPN1LW transcription start site, abolishes transcriptional activation of an otherwise structurally normal L/M opsin gene array. Because the LCR is the sole enhancer shared by the entire tandem gene array, its loss silences all downstream opsin genes (Gardner et al. 2009; OMIM 300824).
  2. Hybrid gene formation + inactivating point mutation (~55–60% of families): Nonallelic homologous recombination (NAHR) between the highly homologous (>98% identical) OPN1LW and OPN1MW sequences reduces the array to a single gene (often an L/M hybrid), which then acquires an inactivating missense or nonsense mutation. The most common recurrent point mutations are Cys203Arg (C203R), Arg247Ter (R247X), and Pro307Leu (P307L); C203R disrupts a disulfide bond required for opsin folding and is the single most frequent BCM-causing variant (IOVS C203R study; Gardner et al. 2009).
  3. Exon deletions / rare interchange (mosaic) haplotypes (uncommon): Deletion of individual exons (e.g., exon 2 or exon 3) within the single remaining opsin gene, or rare L/M "interchange" haplotypes generated by gene conversion at polymorphic exon-3 positions, can also abolish function (Gardner et al. 2009; Sci Rep, Ueno et al. 2018).

Large de novo structural deletions spanning the entire LCR–gene-cluster region (e.g., a documented 73,128-bp deletion) have also been reported as sporadic events (BMC Med Genet 2018), and high-resolution microarray studies have revealed a broader landscape of complex Xq28 structural variants (deletions, duplications, and combined rearrangements) than previously appreciated (PNAS 2022, PMC9271157).

Risk Factors

  • Genetic: Male sex (hemizygosity for the single X chromosome) is the dominant risk factor; any pathogenic variant fully inactivating both OPN1LW and OPN1MW function confers disease. Family history of X-linked color vision deficiency/BCM in maternal male relatives is a strong indicator.
  • Founder/recurrent mutations: The C203R hybrid-gene mutation and several recurrent LCR deletions behave as founder mutations recurring across unrelated families of diverse ancestry, reflecting the intrinsic recombination-prone architecture of the locus rather than a single ancestral haplotype in most populations; specific founder haplotypes (e.g., a complex 3-kb LCR deletion plus an inserted aberrant OPN1MW gene) have been documented in individual pedigrees (PubMed 26153062).
  • Locus architecture as an intrinsic risk factor: The tandem, near-identical (>98%) sequence homology between OPN1LW and OPN1MW predisposes the region to frequent unequal (nonallelic homologous) recombination and gene conversion, independently of any external exposure — this structural instability is itself the principal "risk factor" driving new mutational events in the population (ScienceDirect OPN1MW overview).
  • Environmental/lifestyle: None identified; BCM is not associated with toxins, occupational exposures, maternal illness, or age-related risk.

Protective Factors

No genetic or environmental protective factors are described in the literature; because BCM is a fully penetrant loss-of-function disorder in hemizygous males, there is no known modifier that prevents disease expression once both opsin genes are inactivated. In carrier females, retention of a normal X chromosome (and favorable X-inactivation ratios) is protective against full phenotypic expression (see Section 9).

Gene-Environment Interactions

No gene-environment interactions have been established; BCM is a purely monogenic, cell-autonomous photopigment-deficiency disorder unaffected by diet, toxins, or infection.

3. Phenotypes

Core Phenotype Set (with suggested HPO terms)

Phenotype Type Onset/Course Frequency Suggested HPO term
Severely impaired color vision (blue-cone/tritan-only discrimination) Symptom/clinical sign Congenital, stationary Universal (defining feature) HP:0000551 (Impaired color vision) / HP:0007663 (Reduced visual acuity) related terms; consider HP:0000546 (Blindness) not applicable — use color-vision-specific term
Reduced visual acuity (20/60–20/200; 6/24–6/60) Clinical sign Congenital, may slowly worsen Universal HP:0000572 (Visual impairment) / HP:0000505 (Visual impairment)
Pendular nystagmus Clinical sign Infantile onset, may improve with age Very frequent HP:0000640 (Nystagmus) / HP:0001348 (Pendular nystagmus)
Photophobia / hemeralopia (day blindness) Symptom Congenital, may persist Very frequent HP:0000613 (Photophobia)
Myopia (often high/progressive) Clinical sign Childhood onset Frequent–very frequent HP:0000545 (Myopia) / HP:0011003 (High myopia)
Foveal ellipsoid zone (EZ) disruption on OCT Imaging/laboratory finding Present from early childhood Frequent (no direct HPO; map to macular imaging findings, e.g., HP:0007675 "Retinal atrophy" for advanced changes)
Progressive foveal/macular thinning and atrophy (later in life) Clinical sign, progressive Adolescent/adult onset, slowly progressive Occasional–frequent (reported in older cohorts) HP:0000608 (Macular atrophy)
Preserved tritan (blue-yellow) discrimination Clinical sign Congenital Universal (distinguishing feature) —
Absent 30-Hz photopic (L/M cone) ERG with normal/near-normal rod ERG Laboratory abnormality Congenital, stationary in most Universal HP:0000550 (Abnormal electroretinogram)

Phenotype Characteristics

  • Age of onset: Congenital/early infancy — most children present by 3–6 months with nystagmus, photophobia, and poor fixation (Wikipedia; Vision Research review).
  • Severity: Visual acuity ranges from roughly 20/60 to 20/200 (6/24–6/60), generally better than complete (rod) achromatopsia (typically 20/200 or worse) (Mol Vis 2009).
  • Progression: BCM has traditionally been considered a stationary cone dysfunction syndrome, but longitudinal OCT and psychophysical studies show a slow, progressive component in a subset of patients, particularly with advancing age — progressive thinning of the foveal outer nuclear layer (ONL), shortening of cone outer segments, and eventual macular atrophy in older individuals (Michaelides et al., PMID:15094734; Ophthalmology Science OCT study, PMC9521040). Genotype strongly influences the rate of progression: patients with the C203R missense mutation show markedly slower, decades-longer preservation of foveal ONL thickness and delayed ellipsoid-zone (IS/OS) disruption compared with patients carrying large deletion mutations, who progress to outer retinal atrophy considerably faster (IOVS, "C203R Missense Mutation or Large Deletion Mutations").
  • Frequency of individual signs: Nystagmus and photophobia are near-universal at presentation; nystagmus amplitude frequently decreases (but rarely fully resolves) with age. Myopia, often significant, is very common and is a useful distinguishing feature from achromatopsia (in which hyperopia is more typical).

Quality of Life Impact

Reduced visual acuity, glare sensitivity, and profound color-vision loss impair reading, mobility, driving eligibility, and educational/occupational tasks requiring color discrimination. Clinical-trial-readiness studies have specifically developed and validated reading performance and color vision outcome measures for BCM populations, reflecting the functional impact on literacy and daily tasks (TVST Reading Performance study, PMC7726588; TVST Color Vision Outcome Measures). Photophobia and nystagmus further affect outdoor mobility and can carry psychosocial burden in childhood.

4. Genetic/Molecular Information

Causal Genes

  • OPN1LW (Opsin 1, Long-Wave-Sensitive; red/L-cone opsin) — OMIM *300822, Xq28
  • OPN1MW (Opsin 1, Medium-Wave-Sensitive; green/M-cone opsin) — OMIM *300821, Xq28
  • Locus Control Region (LCR) — OMIM 300824, a cis-regulatory element (not itself protein-coding) located 3.1–3.7 kb 5′ of the gene array, required in trans*-independent fashion for expression of both downstream genes.

Both BCM causal genes must lose function (combined L+M opsin loss) for the phenotype to manifest; loss of only one gene produces ordinary red-green color blindness (protanopia/deuteranopia), not BCM.

Gene Structure and Regulation

OPN1LW and OPN1MW are arranged head-to-tail in a tandem array on Xq28, sharing >98% sequence identity (including introns) and only ~19 differing amino acids between the encoded L and M opsins (~96% protein identity), while both are only ~40% homologous to the S-cone opsin gene OPN1SW (Wikipedia). A single LCR located upstream of the array physically loops to interact with the proximal promoter of either the OPN1LW gene or one of the OPN1MW copies, enforcing mutually exclusive, stochastic expression of a single opsin gene per cone photoreceptor; the LCR's regulatory reach is limited to roughly the first two genes in the array, explaining why extra downstream OPN1MW copies are transcriptionally silent in normal individuals (Vision Research review).

Pathogenic Variant Categories

  • Variant classification (ACMG/AMP): Recurrent nonsense (R247X) and structurally disruptive missense variants (C203R — disrupts a conserved disulfide bond) are classified as pathogenic in ClinVar; large deletions of the LCR or gene array are similarly pathogenic (ClinVar RCV000011249).
  • Variant types: Large structural deletions (LCR, whole gene, or gene-cluster deletions), missense (C203R, P307L), nonsense (R247X), exonic deletions, and rare exon-3 interchange/hybrid alleles.
  • Allele frequency: BCM-causing variants are individually very rare/private or recurrent-but-low-frequency in population databases (gnomAD), consistent with an X-linked disorder under purifying selection in affected males; specific population allele frequencies for LCR deletions or C203R are not well captured in standard gnomAD summary statistics due to the structural complexity of the locus (segmental duplication/homology confounds short-read mapping).
  • Origin: Predominantly germline; can be inherited from a carrier mother or arise as a de novo structural event (documented de novo 73-kb deletions) in sporadic cases with no family history (BMC Med Genet 2018).
  • Functional consequence: Loss of function — either complete transcriptional silencing (LCR/array deletion) or loss of functional opsin protein (misfolding/instability from missense variants such as C203R, or truncation from nonsense variants).

Modifier Genes

No independent modifier genes are firmly established, but genotype at the primary BCM locus itself acts as a phenotypic modifier of progression rate (C203R vs. deletion genotypes, above). A single case report describes a digenic-like interaction between OPN1LW/OPN1MW variants and a concomitant GPR143 variant (the ocular albinism gene) producing BCM with superimposed foveal hypoplasia, illustrating how a second unrelated X-linked locus can modify the retinal phenotype in an individual patient (PMC8395340).

Epigenetic Information

The defining regulatory mechanism of the normal locus (LCR-driven, X-inactivation-coupled, single-active-gene choice per cone) is itself an epigenetic/allelic-exclusion phenomenon. In carrier females, random X-chromosome inactivation (XCI) determines which X-linked opsin allele is expressed in each cone, and skewed XCI toward the mutant allele is the proposed mechanism underlying variable, sometimes symptomatic, carrier phenotypes (see Section 9) (PubMed 22998501). No disease-specific DNA methylation or histone-modification signature has been characterized beyond this XCI mechanism.

Chromosomal Abnormalities

BCM is caused by submicroscopic structural variants (kilobase-scale deletions/duplications/rearrangements) rather than classical whole-chromosome aneuploidy or large cytogenetically visible translocations. High-resolution microarray and long-read sequencing studies have revealed a broader-than-expected landscape of complex Xq28 rearrangements (combined deletions, duplications, and inversions) at this locus in BCM patients and carriers (PNAS 2022; PubMed 26153062).

5. Environmental Information

BCM is a purely genetic disorder with no established environmental, lifestyle, or infectious contributing factors. No toxin, occupational exposure, dietary factor, or pathogen has been implicated in either causing BCM or modifying its severity. This section is not applicable beyond noting the absence of such associations in the literature reviewed.

6. Mechanism / Pathophysiology

Causal Chain

  1. Molecular trigger: LCR deletion, hybrid-gene formation with inactivating point mutation, or exonic deletion → loss of functional L- and M-opsin (photopigment) protein expression in cone photoreceptors that would normally express OPN1LW or OPN1MW.
  2. Cellular consequence: L- and M-cones fail to synthesize functional visual pigment. Because opsin apoprotein (in complex with 11-cis-retinal) is required for normal outer segment disc morphogenesis and stability, "opsin-null" cones fail to elaborate normal outer segments and are structurally compromised from early development, even though the cell bodies may initially survive (Vision Research review; PubMed 20638402 — "Deletion of the X-linked opsin gene array locus control region (LCR) results in disruption of the cone mosaic").
  3. Downstream degeneration: Over time, opsin-deficient L/M cones undergo progressive dysfunction and, in a genotype-dependent manner, degeneration — with slower attrition in C203R (a partially foldable/mistrafficked missense protein may retain some residual structural support) versus faster attrition in complete-deletion genotypes (no protein product at all) (IOVS C203R study).
  4. Tissue-level outcome: Progressive thinning of the foveal outer nuclear layer, ellipsoid zone (inner segment/outer segment junction) disruption on OCT, and eventual foveal/macular atrophy in a subset of older patients — while S-cones and rods, whose opsin genes (OPN1SW, RHO) are unaffected, remain structurally and functionally intact, preserving blue-cone and scotopic (rod) vision (Ophthalmology Science OCT comparison, PMC9521040).
  5. Clinical manifestation: The combination of absent L/M-cone signal with intact S-cone and rod signal produces the clinical triad of severe red-green (and functionally near-total) color vision loss, reduced but non-zero visual acuity (mediated by residual S-cones/rods and the small central S-cone-free zone), nystagmus (from poor foveal fixation input in infancy), photophobia (relative rod/S-cone over-stimulation without normal L/M gain control), and myopia (a common secondary refractive association in congenital cone dysfunction syndromes).

Upstream vs. Downstream Mechanisms

  • Upstream (initiating): Genomic structural/point mutation events at the OPN1LW/OPN1MW/LCR locus (germline or de novo).
  • Midstream: Failure of opsin transcription/translation/protein folding → absent or non-functional visual pigment.
  • Downstream: Cone outer segment morphogenesis failure → progressive (genotype-dependent) foveal cone structural loss → clinical visual/color phenotype, with the latest downstream event being macular atrophy in a subset of aging patients.

Cell Types and Biological Processes Involved

  • Cell types: Long-wavelength-sensitive cone photoreceptor; medium-wavelength-sensitive cone photoreceptor (both spared: short-wavelength-sensitive cone photoreceptor and rod photoreceptor). Suggested Cell Ontology (CL) terms: CL:0000573 (retinal cone cell), with L/M-cone subtype distinctions less finely resolved in CL; CL:0000604 (retinal rod cell) for the spared population.
  • Biological processes (GO terms):
  • GO:0007601 (visual perception)
  • GO:0016038 (absorption of visible light) / GO:0009583 (detection of light stimulus)
  • GO:0007602 (phototransduction)
  • GO:0035845 (photoreceptor cell outer segment organization)
  • GO:0046549 (retinal cone cell development)
  • GO:0006355 (regulation of transcription, DNA-templated) — for LCR enhancer function
  • Molecular function: GO:0008020 (G-protein coupled photoreceptor activity) — opsin as a light-activated GPCR.

Protein Dysfunction

  • Loss of function is the unifying mechanism: complete absence of opsin protein (deletion genotypes) or an unstable/misfolded, functionally null opsin (C203R disrupts a disulfide bond critical for correct tertiary folding of the seven-transmembrane opsin GPCR, leading to endoplasmic reticulum retention/degradation and failure to reach or function properly in the outer segment membrane) (IOVS C203R study; JCI Insight, "Structural and functional rescue of cones carrying...C203R"). No gain-of-function or dominant-negative mechanism is implicated.

Molecular Profiling / Advanced Technologies

Given BCM's rarity and the technical difficulty of live human cone-transcriptomic sampling, most molecular characterization has relied on: (a) targeted long-range PCR, Southern blotting, and microarray/optical genome mapping of the Xq28 locus to resolve structural variants (PNAS 2022; PubMed 26153062); (b) high-resolution adaptive optics and OCT imaging as an in vivo structural proxy for cone survival (Ophthalmology Science, PMC9521040); and (c) mouse-model transcriptomic/histologic studies of engineered Opn1mw-null and C198R-knock-in retinas (the murine equivalent of human C203R) to dissect degeneration kinetics (Communications Biology 2025; PMC12036465). No large-scale human single-cell/spatial transcriptomic or CRISPR functional-genomics dataset specific to BCM was identified in this search.

7. Anatomical Structures Affected

Organ Level

  • Primary organ: Eye (retina), specifically the posterior pole/macula/fovea, where cone density is highest.
  • Secondary/complications: Secondary refractive changes (myopia); no major involvement of other organ systems — BCM is an isolated, non-syndromic ocular disorder (except in rare digenic cases with concurrent albinism-related genes producing additional anterior-segment/foveal hypoplasia features).
  • Body system: Visual system / sensory nervous system.

Suggested UBERON terms: UBERON:0000966 (retina), UBERON:0001782 (fovea centralis), UBERON:0001789 (macula lutea).

Tissue and Cell Level

  • Tissue: Neurosensory retina, specifically the outer retina (photoreceptor layer) and outer nuclear layer.
  • Cell populations: L-cone photoreceptors and M-cone photoreceptors (primarily affected/lost); S-cone photoreceptors and rod photoreceptors (spared). Suggested CL term: CL:0000573 (retinal cone cell); more specific L/M vs. S subtypes are not yet finely distinguished in CL nomenclature but can be annotated via free-text qualifiers.

Subcellular Level

  • Cellular compartments: Cone outer segment (site of opsin protein localization and phototransduction) is structurally deficient/absent in affected cones; endoplasmic reticulum (site of opsin misfolding/retention for missense variants like C203R). Suggested GO Cellular Component terms: GO:0001750 (photoreceptor outer segment), GO:0005783 (endoplasmic reticulum).

Localization

  • Site: Central retina/fovea, where cone density is greatest and where visual acuity loss and OCT abnormalities are most pronounced and earliest to progress to atrophy.
  • Laterality: Bilateral and symmetric, consistent with a systemic (whole-body, X-linked) genetic mechanism rather than a focal or asymmetric insult.

8. Temporal Development

Onset

  • Age of onset: Congenital — signs (nystagmus, poor fixation, photophobia) typically noted in the first months of life; formal diagnosis often made in early-to-mid childhood once color vision and acuity can be more precisely tested (Vision Research review).
  • Onset pattern: Congenital/insidious — present from birth rather than an acute event.

Progression

  • Disease course pattern: Historically classified as a stationary congenital cone dysfunction syndrome, but longitudinal cohort and OCT studies demonstrate a slow, genotype-dependent progressive component in many patients, particularly evident by young-to-mid adulthood, with foveal ONL thinning, ellipsoid zone disruption, and in a minority of patients (~3% in one comparative OCT cohort) frank macular atrophy at later ages (Michaelides et al. PMID:15094734; Ophthalmology Science, PMC9521040).
  • Progression rate: Variable by genotype — C203R-associated disease progresses markedly more slowly (foveal ONL preserved for decades longer) than large-deletion-associated disease, which shows earlier ellipsoid-zone loss (IOVS C203R study).
  • Disease duration: Chronic, lifelong — there is no spontaneous resolution of the underlying cone dysfunction, though nystagmus amplitude often lessens with age.

Patterns

  • Remission: No spontaneous remission of the underlying color/acuity deficit; nystagmus may clinically improve/dampen with age even though the molecular lesion is unchanged.
  • Critical periods: The developing visual system in infancy (fixation, nystagmus circuitry) is a period of particular clinical relevance, and any future gene-replacement therapy is hypothesized to have the greatest benefit if administered before substantial cone structural loss has occurred — mouse studies indicate a shrinking "therapeutic window" for AAV-mediated rescue with increasing age/degeneration (PMC12036465, "Molecular Mechanisms Limiting the Therapeutic Window of AAV Gene Therapy in Mouse Models of BCM").

9. Inheritance and Population

Epidemiology

  • Prevalence: Estimated at approximately 1 in 100,000 individuals overall, with Orphanet classifying prevalence as 1–9 per 100,000 (Orphanet ORPHA:16); some sources cite a male incidence range of roughly 1 in 40,000 to 1 in 100,000.
  • Sex-specific incidence: Because it is X-linked recessive, BCM is overwhelmingly a disease of males; fully symptomatic disease in females is exceptionally rare (estimated by some sources at roughly 1 in tens of billions of female births under strict biallelic assumptions, though skewed X-inactivation carrier phenotypes are more commonly reported than fully biallelic female cases).

Inheritance Pattern and Genetic Parameters

  • Mode of inheritance: X-linked recessive.
  • Penetrance: Complete/high penetrance in hemizygous males carrying a fully inactivating genotype.
  • Expressivity: Variable — genotype (C203R vs. deletion vs. exon-deletion) significantly influences severity and, especially, the rate of later-life progression to macular atrophy (Section 8).
  • Genetic anticipation: Not reported for BCM; this is not a repeat-expansion disorder.
  • Germline mosaicism: Not specifically well-documented in the literature reviewed, though possible in principle for any de novo X-linked structural variant.
  • Founder effects: Recurrent structural (LCR deletion) and point-mutation (C203R) alleles behave as low-frequency founder/recurrent mutations across multiple unrelated pedigrees, attributable to the intrinsically recombinogenic locus architecture rather than a single shared ancestral haplotype in most reported cohorts; specific multi-family founder haplotypes (e.g., a 3-kb LCR deletion plus inserted aberrant OPN1MW gene) have also been documented (PubMed 26153062).
  • Carrier frequency: Not precisely established in large population databases due to locus mapping difficulty (segmental duplication); inferred to be low, consistent with disease rarity.
  • Consanguinity: Not a major factor for an X-linked recessive disorder transmitted maternally (relevant mainly to autosomal recessive conditions), though it can theoretically increase risk of an affected homozygous female in rare pedigrees.

Carrier (Female) Phenotype

Female carriers are typically unaffected or only mildly/subclinically affected due to random X-inactivation, but can show detectable abnormalities: on average, about half of cones fated to express L or M opsin fail to make photopigment, producing a disrupted cone mosaic with reduced density and abnormal spatial organization on adaptive optics imaging, and multifocal ERG evidence of patchy dysfunction (PubMed 20638402). In rare cases of skewed X-inactivation, carrier females can manifest a clinically overt BCM-like phenotype despite heterozygosity (PubMed 22998501, "Blue cone monochromatism in a female due to skewed X-inactivation").

Population Demographics

  • Affected populations: No strong ethnic/geographic clustering has been robustly established in the literature surveyed; cases and distinct causal variants have been reported across European, Japanese, and other populations, consistent with the locus's intrinsic mutability across diverse genetic backgrounds (Sci Rep, Japanese cohort; Human Genome Variation, Japanese families).
  • Sex ratio: Essentially all-male among clinically ascertained probands, consistent with X-linked recessive inheritance; carrier females are asymptomatic-to-mildly-affected.
  • Age distribution: Presentation across all pediatric and adult age ranges (congenital onset with lifelong persistence); cohort studies specifically include pediatric-through-elderly patients to characterize the slow, genotype-dependent progression described above.

10. Diagnostics

Clinical Tests

  • Electroretinogram (ERG): The key diagnostic test. Standard rod-specific and maximal (mixed rod-cone) ERG responses are typically normal or near-normal, while the 30-Hz photopic flicker ERG (which is L/M-cone-driven) is undetectable or severely reduced. Specialized S-cone-isolating stimuli elicit a characteristic blue-flash response (S-cone b-wave, amplitude ~5–10 µV, implicit time ~35–45 ms) that is essentially absent to red/green flashes of any intensity — this dissociation (present S-cone/rod signal, absent L/M-cone signal) is the diagnostic hallmark distinguishing BCM from complete (rod) achromatopsia, in which all cone signals are extinguished (Springer ERG chapter; Wikipedia). S-cone contributions to oscillatory potentials have also been specifically characterized as an ancillary ERG signature (PMC11236933).
  • Color vision testing: Farnsworth D-15 and Farnsworth-Munsell 100-Hue tests demonstrate severe generalized color confusion with relatively better-preserved tritan (blue-yellow) axis performance; the Berson test and other specialized instruments are also used.
  • Imaging (OCT): Optical coherence tomography shows foveal ellipsoid zone (EZ) disruption and outer nuclear layer thinning from an early age (mean foveolar ONL ~60% of normal in patients aged 5–20 years), with slow further thinning and occasional macular atrophy with age (Ophthalmology Science, PMC9521040). Adaptive optics imaging can further resolve residual (structurally abnormal, shortened-outer-segment) cone mosaics.
  • Family history: Reconstruction of an X-linked recessive pedigree (affected males, carrier females, no male-to-male transmission) supports the diagnosis.

Genetic Testing

  • Recommended approach: Targeted analysis of the OPN1LW/OPN1MW gene cluster and LCR, given the segmental-duplication/high-homology architecture that confounds standard short-read whole-exome sequencing. Specialized long-range PCR, Southern blotting, high-resolution microarray (chromosomal microarray/CMA equivalent for this locus), or long-read sequencing/optical genome mapping are typically required to accurately resolve deletions, hybrid genes, and copy-number changes at Xq28 (PNAS 2022; PubMed 26153062). Orphanet lists a dedicated diagnostic test entry for OPN1LW/OPN1MW analysis (Orphanet diagnostic test 317156).
  • WES/WGS utility: Standard WES pipelines frequently miss or misclassify variants at this locus due to near-identical paralog sequences, so a negative standard WES/WGS result does not exclude BCM; specialized bioinformatic pipelines or orthogonal structural-variant-focused testing are advised when BCM is clinically suspected.
  • Single-gene/targeted testing: Direct amplicon sequencing or MLPA-style copy-number analysis of the OPN1LW/OPN1MW/LCR region is the most sensitive first-line molecular test.
  • Chromosomal microarray, karyotyping, and FISH are generally not sensitive enough for these submicroscopic (kilobase-scale) rearrangements and are not first-line for BCM specifically.

Clinical Diagnostic Criteria and Differential Diagnosis

There is no formal DSM/ICD structured diagnostic algorithm; diagnosis rests on the clinical triad (nystagmus/photophobia/myopia with poor acuity), ERG dissociation pattern, color-vision test results, and confirmatory molecular genetics. Key differential diagnoses: - Achromatopsia (rod monochromatism), autosomal recessive (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, ATF6), which affects all three cone types (not just L/M), typically produces worse visual acuity, more frequent foveal hypoplasia, and hyperopia rather than myopia — BCM patients have relatively better acuity, less-frequent foveal hypoplasia, and preserved tritan discrimination as distinguishing features (PMC9521040; GeneReviews Achromatopsia). - Other cone dystrophies/cone-rod dystrophies (progressive, often autosomal, with more marked rod involvement over time) should also be excluded via ERG and genetic testing.

Screening

No population-based newborn or carrier screening program specifically targets BCM given its rarity; genetic counseling and cascade testing of at-risk maternal relatives in known BCM families is the practical screening approach once a proband's causal variant is identified.

11. Outcome/Prognosis

Survival and Mortality

BCM is a purely ocular disorder with no systemic organ involvement and no reduction in life expectancy or increased mortality; it is not a life-limiting condition.

Morbidity and Function

  • Visual morbidity: Lifelong visual acuity impairment (20/60–20/200 range), profound color-vision deficit, photophobia, and nystagmus produce measurable functional impact on reading speed, mobility, and tasks requiring fine visual discrimination or color identification. Quality-of-life/functional outcome measures (reading performance, color-discrimination task batteries) have been specifically validated in BCM cohorts to quantify this burden and to serve as trial endpoints (TVST Reading Performance, PMC7726588; PLOS ONE Visual Function Outcome Measures, PMC4409040).
  • Disability outcomes: Most patients qualify as visually impaired/low vision by acuity criteria but retain functional (non-blind) vision; complete blindness is not typical.

Disease Course

  • Complications: The principal late complication is progressive foveal/macular atrophy in a subset of (typically older, and especially deletion-genotype) patients, which can further reduce visual acuity beyond the baseline congenital deficit.
  • Recovery potential: No spontaneous recovery of L/M-cone function occurs with current standard care; the disorder is not reversible without investigational gene therapy (Section 12).

Prediction / Prognostic Factors

  • Genotype is the principal prognostic factor identified in the literature: the C203R missense mutation is associated with a substantially more indolent course (slower foveal ONL thinning and IS/OS disruption) than large deletion genotypes, which progress to structural retinal atrophy earlier and more rapidly (IOVS C203R study). This genotype-severity correlation is directly relevant to patient counseling and to gene-therapy trial patient selection/timing, since a shrinking therapeutic window with age/degeneration has been demonstrated in animal models (PMC12036465).

12. Treatment

Current Standard of Care (Supportive/Symptomatic — No Disease-Modifying Therapy Approved)

There is no curative or disease-modifying therapy currently approved for BCM; management is entirely supportive: - Tinted lenses/filters: Magenta- or brown-tinted lenses or contact lenses reduce photophobia and can enhance color contrast; magenta tints are specifically favored because they protect rods from over-stimulation while allowing maximal light transmission to stimulate the residual S-cones (BCM Families Foundation clinical management). Suggested NCIT term: NCIT:C15747 (Supportive Care) as the general category; no specific NCIT code exists for "tinted lens therapy," though it can be mapped under low-vision rehabilitation/device categories. - Low vision aids: Magnifiers, telescopic devices, and adaptive technology (tablet/e-reader adjustable lighting, color-identification apps/colorimeters, screen-reader software) support daily function, particularly reading and color-dependent tasks. - Refractive correction: Standard correction of myopia with spectacles/contact lenses. - Periodic ophthalmologic monitoring: Regular follow-up (including OCT) to track the genotype-dependent risk of late progressive macular atrophy. - NCIT terms applicable to current management: NCIT:C15302 (Physical Therapy) — not typically relevant; more applicable are NCIT:C15747 (Supportive Care) and device/low-vision-aid categories; NCIT:C15240 (Genetic Counseling) for family counseling.

Experimental / Investigational Gene Therapy

BCM is a leading candidate for AAV-mediated gene supplementation therapy because it is a monogenic, cell-autonomous, loss-of-function disorder amenable to opsin gene replacement in surviving cones: - Preclinical vector development — ADVM-062 (Adverum Biotechnologies): An AAV.7m8-capsid vector (an AAV2 variant with enhanced foveal cone transduction after intravitreal, rather than subretinal, injection) expressing human L-opsin under a synthetic cone-specific promoter (MNTC cassette). GLP toxicology/biodistribution studies showed the vector was well tolerated up to 5×10¹¹ vg/eye with dose-dependent hL-opsin expression and functional opsin activity in non-human primate cones, supporting its potential as a single intravitreal injection therapy (Molecular Therapy 2023, PMC10362383). - Preclinical academic programs: The Vision Center at Children's Hospital Los Angeles is developing a Phase 1 clinical trial protocol for the first gene therapy specifically for boys with BCM, supported by a $4.7 million grant from the California Institute for Regenerative Medicine (CIRM) (Managed Healthcare Executive); orphan drug designation has been granted to at least one BCM gene therapy candidate (CGTlive, "Blue Cone Monochromacy Gene Therapy Gets Orphan Drug Designation"). - Mouse model proof-of-concept: AAV-mediated L/M-opsin gene replacement rescues cone function and partially restores outer segment structure in Opn1lw/Opn1mw double-knockout and C198R (mouse equivalent of human C203R) knock-in models, and in an all-cone (Nrl-null) BCM model, using various capsids (AAV8-Y733F shown to outperform AAV5 in some comparisons) (Sci Rep 2017, PMC5532293; Molecular Therapy Advances 2025; JCI Insight, C203R structural/functional rescue). - Key translational caveat — the therapeutic window: Recent mouse studies specifically demonstrate that AAV rescue efficacy declines with age/disease duration, associated with mislocalized mitochondria, compromised connecting cilia, and reduced transgene expression in aged, degenerating cones — implying that human gene therapy trials will likely need to target patients relatively early in the disease course, before extensive cone structural loss, for maximal benefit (Communications Biology 2025 / PMC12036465). - As of this review, no completed or actively enrolling registered human clinical trial (ClinicalTrials.gov NCT identifier) for BCM gene therapy was identified in available search results; development remains at the advanced preclinical/IND-enabling stage for the programs identified (ADVM-062 and the CHLA-CIRM program), with trial readiness work (validated outcome measures — see below) actively underway. - Suggested NCIT term for the investigational modality: NCIT:C15238 (Gene Therapy).

Trial Readiness / Outcome Measures Development

Because BCM has no natural endpoint analogous to a tumor response or a lab value, substantial dedicated methodological work has defined and validated functional outcome measures for future gene therapy trials, including: standardized visual acuity and contrast sensitivity protocols, a validated reading performance metric, and structured color vision discrimination tasks with quantified test-retest reliability (PLOS ONE / PMC4409040; TVST Reading Performance / PMC7726588; TVST Color Vision Outcome Measures), as well as detailed natural-history OCT/retinal-structure studies intended to define clinical endpoints and inform optimal patient/age selection for L-opsin gene therapy trials (PMC11477341).

Treatment Strategy Notes

There is no combination-therapy or personalized-medicine algorithm beyond genotype-informed prognostic counseling (C203R vs. deletion genotype) and — prospectively — genotype/age-informed patient selection for gene therapy trials given the demonstrated shrinking therapeutic window.

13. Prevention

Prevention Levels

  • Primary prevention: Not applicable in the traditional sense (no modifiable environmental exposure to avoid); the only "primary prevention" pathway is reproductive/genetic counseling for known carrier families, including options such as preimplantation genetic diagnosis (PGD) or prenatal testing for at-risk pregnancies once a family's causal variant is characterized.
  • Secondary prevention: Early recognition of the classic infantile triad (nystagmus, photophobia, poor fixation) with prompt ERG/genetic testing allows earlier diagnosis, appropriate low-vision intervention, and — in the future — earlier eligibility for gene therapy while cone structure is best preserved (directly relevant given the genotype/age-dependent progression and shrinking therapeutic window discussed above).
  • Tertiary prevention: Regular ophthalmologic surveillance (including OCT) to detect and manage the onset of progressive macular atrophy, tinted-lens/low-vision interventions to minimize functional disability, and myopia correction to optimize best-corrected visual function.

Immunization

Not applicable — BCM is not an infectious or immune-mediated disease.

Screening and Early Detection

  • No population-based newborn screening program exists for BCM specifically (unlike some metabolic disorders).
  • Genetic/carrier screening and cascade testing: Once a proband's OPN1LW/OPN1MW/LCR variant is identified, cascade testing of at-risk maternal relatives (obligate and possible carrier females, at-risk male relatives) is the practical form of "screening" in this disorder, supporting informed reproductive decision-making.
  • Risk stratification: Family pedigree analysis (X-linked recessive pattern) combined with confirmed molecular diagnosis in a proband allows precise risk stratification for relatives.

Counseling

Genetic counseling is central to BCM management for family planning — explaining X-linked recessive transmission (obligate carrier status of daughters of affected males; 50% carrier risk for daughters, 50% affected risk for sons of carrier mothers), clarifying that carrier females are usually unaffected or mildly affected (with rare exceptions from skewed X-inactivation), and discussing reproductive options (BCM Families Foundation transmission page; NCIT:C15240 Genetic Counseling).

Public Health / Environmental Interventions

Not applicable — there are no environmental or public-health interventions relevant to this purely genetic disorder.

Prophylaxis

No pharmacologic or procedural prophylaxis exists; management is entirely supportive/monitoring-based as described above (Section 12).

14. Other Species / Natural Disease

Taxonomy

No naturally occurring companion-animal or wildlife disease directly homologous to human BCM (i.e., a spontaneous L/M-opsin-locus loss-of-function disorder) was identified in the available search results. Most non-human mammals (with the exception of catarrhine primates) are naturally dichromatic, possessing only a single long/middle-wavelength cone opsin gene plus an S-opsin gene — meaning the specific "duplicated-gene-array-with-shared-LCR" architecture that predisposes humans (and other catarrhine primates) to BCM is itself a primate-specific genomic feature, limiting natural cross-species disease models. Relevant taxonomic context: NCBITaxon:9606 (Homo sapiens); the L/M-opsin gene duplication is shared with Old World monkeys and apes (Catarrhini).

Model Organism Orthologs

  • Mouse (Mus musculus): Opn1mw (mouse M-opsin gene; ortholog of human OPN1MW/OPN1LW, since mice have a single M-opsin gene rather than the human tandem L/M array) and Opn1sw (S-opsin). NCBI Gene mouse Opn1mw is the key ortholog engineered in BCM models (see Section 15).
  • No natural (spontaneously occurring) veterinary BCM-like disease was found in the literature surveyed; all animal "models" identified are engineered (see below), not naturally occurring disease.

Comparative Biology

The evolutionary origin of the human OPN1LW/OPN1MW tandem duplication (from a single ancestral opsin gene via a relatively recent primate-lineage gene duplication event) explains both the disease-predisposing genomic instability (segmental duplication prone to NAHR) and the absence of a natural non-primate counterpart — most mammalian model species must be genetically engineered to recapitulate the human gene-loss phenotype.

Transmission

Not applicable — BCM is a non-infectious, non-zoonotic, purely genetic disorder.

15. Model Organisms

Model Types and Genetic Models

  • Mouse (Mus musculus) — the dominant model system:
  • Opn1mw/Opn1sw double-knockout (DKO) mice: Complete genetic ablation of the murine M- and S-opsin genes, producing an "all-rod-driven-cone-loss" model analogous to complete L/M-opsin loss in humans (Sci Rep 2017, PMC5532293).
  • Opn1mw^C198R^/Opn1sw^−/−^ knock-in ("C198R") mice: A missense knock-in engineered to model the human C203R hybrid-gene missense mutation (the single most common human BCM genotype), allowing direct comparison of missense- versus deletion/null-genotype degeneration kinetics in a controlled genetic background (PMC12036465; Communications Biology 2025).
  • All-cone retina models (e.g., Opn1mw⁻/⁻/Opn1sw⁻/⁻/Nrl⁻/− mice): Combine opsin knockouts with Nrl loss (which converts the retina to an all-cone phenotype, eliminating rods) to increase the proportion of cone photoreceptors available for study and gene-therapy testing, since mice are naturally rod-dominant and have far fewer cones than the human macula (Molecular Therapy Advances 2025).
  • Induced/AAV-treated models: The same knockout/knock-in lines are used as the substrate for AAV-mediated L/M-opsin gene replacement studies (Section 12).
  • Non-human primates (used for preclinical vector biodistribution/toxicology, not as genetic disease models): Cynomolgus/rhesus macaques were used in GLP toxicology and biodistribution studies of the ADVM-062 intravitreal vector, leveraging the primate eye's similarity in size and foveal cone density to the human eye and the fact that primates share the tandem L/M-opsin gene architecture (Molecular Therapy 2023, PMC10362383; ASGCT 2022 poster).

Model Characteristics — Phenotype Recapitulation and Limitations

  • Recapitulation: Mouse knockout/knock-in models faithfully recapitulate the core molecular lesion (loss of functional M/L-opsin) and reproduce key downstream cellular findings seen in human BCM retina — absent/abnormal cone outer segments, progressive cone structural degeneration, and (in the C198R knock-in) a slower degeneration course than in full-null models, mirroring the human C203R-vs-deletion genotype-severity correlation (PMC12036465).
  • Limitations: Mice lack a true fovea and have a rod-dominant, cone-sparse retina, substantially limiting direct translation of cone density/structural findings and necessitating all-cone (Nrl-null) or other cone-enriched engineering to increase experimental tractability; mice also possess only a single ancestral M/L-opsin gene (no tandem duplication/shared LCR), so the specific LCR-deletion and hybrid-gene-formation mutational mechanisms that predominate in human BCM cannot be modeled at the genomic-architecture level in mice — only the downstream consequence (opsin loss) is modeled via direct gene knockout/knock-in. Non-human primates better preserve foveal anatomy and gene-array architecture but are far more resource-intensive and are used primarily for vector safety/biodistribution rather than as a genetic disease model per se.

Applications

Mouse models have been used to: (1) establish proof-of-concept that AAV-mediated opsin gene replacement can restore cone function and partially regenerate outer segment structure; (2) directly compare degeneration kinetics and gene-therapy rescue efficacy between missense (C198R) and null/deletion genotypes, informing human genotype-based prognosis; and (3) define the age-dependent "therapeutic window" for gene therapy — a critical translational finding indicating that earlier intervention (before advanced cone degeneration, mitochondrial mislocalization, and connecting-cilium compromise) yields substantially better rescue outcomes (PMC12036465; biorxiv preprint, C203R all-cone rescue).

Resources

Mouse Genome Informatics (MGI) is the primary repository for the Opn1mw/Opn1sw knockout and knock-in alleles described above; no dedicated public repository entry for a BCM-specific "disease model" collection (e.g., in IMPC/KOMP) was specifically identified in this search, suggesting these lines are largely custom/investigator-generated rather than centrally banked as of this review.

Summary of Suggested Ontology Term Mappings

Category Suggested Term(s)
Disease (MONDO) MONDO:0010563
Disease (OMIM) #303700
Disease (Orphanet) ORPHA:16
Causal genes (HGNC symbols) OPN1LW (OMIM 300822); OPN1MW (OMIM 300821); regulatory element LCR (OMIM *300824)
Key phenotypes (HPO) HP:0000640 (Nystagmus); HP:0000613 (Photophobia); HP:0000545 (Myopia); HP:0000572/HP:0000505 (Visual impairment); HP:0000550 (Abnormal electroretinogram); HP:0000608 (Macular atrophy); impaired color vision term
Cell types (CL) CL:0000573 (retinal cone cell); CL:0000604 (retinal rod cell)
Anatomy (UBERON) UBERON:0000966 (retina); UBERON:0001782 (fovea centralis); UBERON:0001789 (macula lutea)
Biological process (GO) GO:0007601 (visual perception); GO:0007602 (phototransduction); GO:0035845 (photoreceptor outer segment organization)
Cellular component (GO) GO:0001750 (photoreceptor outer segment); GO:0005783 (endoplasmic reticulum)
Treatment/intervention (NCIT) NCIT:C15747 (Supportive Care); NCIT:C15238 (Gene Therapy, investigational); NCIT:C15240 (Genetic Counseling)
Model organism gene Mouse Opn1mw, Opn1sw (NCBI Gene)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 20
Resolved 20
Unresolved (possible confabulation) 0
Unverifiable 0

All extracted references resolved successfully.